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ABSTRACT 
 
MODULATION OF IMMUNITY VIA ANTIBODIES DISPLAYED ON IN SITU 
FORMING PEPTIDE CO-ASSEMBLIES 
By 
Yi Wen 
August 2014 
 
Dissertation supervised by Wilson S. Meng, Ph.D. 
Many diseases are associated with disruption of immune homeostasis.  Monoclonal 
antibodies (mAb) targeting soluble antigens or immune cell surface molecules have been 
developed to modulate immunity.  However, systemic administration can lead to severe 
immune related side effects.  This dissertation investigated a versatile platform to display 
antibodies locally in diseased tissues to minimize unwanted systemic exposure.   This 
system is a stimuli-responsive and injectable formulation utilizing in situ forming peptide 
co-assemblies and two linker proteins.  The self-assembling peptides EAK16-II and 
EAKIIH6 co-assemble into fibrous structures with accessible His-tags when exposed to 
salts.  Anti-His-tag antibodies (αH6-IgG) bind to these His-tags and provide fragment 
crystallizable region (Fc) for protein A/G (pAG).  A therapeutic antibody can be 
displayed through non-covalent Fc-pAG interactions.  Proof-of-concept studies 
demonstrate that antibodies were displayed via His-tags through the linker proteins, 
  v 
namely His-tag/αH6-IgG/pAG interactions.  Displayed antibodies remained biologically 
active and were able to bind to cognate antigens.  Upon administration to normal 
subcutaneous space, tumors, or transplant sites, a fluorescent dye labeled IgG was 
retained effectively at the site of injection.  Antibodies targeting a cellular surface antigen 
were loaded onto the peptide co-assembly.  Displayed antibodies were able to interact 
with cellular surface antigens and impede trafficking of target cells, resulting in potential 
therapeutic response in a murine skin transplantation model.  Characterization of the 
peptide co-assembly indicates the His-tagged peptide (EAKIIH6) co-assembled with the 
parent peptide (EAK16-II) in a concentration dependent manner.  Comparing the co-
assembly efficiency of EAKIIH6 to other control peptides implies that EAKIIH6 might 
adopt a β-strand conformation and align with existing EAK16-II β-sheets during co-
assembly.  It was also found that the accessibility of His-tags could be tuned by changing 
the ratio of peptides.  To conclude, these results demonstrate the peptide co-assembly 
based system could be used as a versatile antibody display system to modulate immunity.  
It may have the potential to improve therapeutical outcomes of mAbs as a local antibody 
delivery system, and it could also be utilized as a material strategy to immobilize target 
cells. 
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CHAPTER 1  
Introduction  
Statement of the problem 
Immunity is mediated through cell-cell interactions and various cytokines.  Antigen 
presenting cells (APCs) process and display antigenic peptide on the surface through 
major histocompatibility complexes (MHC) (1).  Helper CD4 T cells are activated by 
APCs via binding of T cell receptor (TCR) to MHC and binding of CD28 to 
costimulatory molecules (i.e. B7) (1).  Immune responses include production of 
immunoglobulin (Ig) and activation of CD8 cytotoxic T cells and macrophages, which 
collectively eliminate the target pathogens (1). 
    The human immune system maintains a delicate balance such that non-self pathogens 
are eliminated but self-molecules are tolerated.  Many diseases, such as autoimmune 
diseases and cancer, are associated with abnormal changes in polarization of immune 
cells.  For example, infiltrating regulatory T cells (Treg) in tumors mediate immune 
tolerance to cancer cells (2-4).  Treg cells produce immune inhibitory cytokines, e.g. IL-
10 and transforming growth factor β (TGF-β), to suppress CD8 T cells and myeloid cells. 
Treg cells also down-regulate the activity of APCs through surface cytotoxic T 
lymphocyte antigen-4 (CTLA-4) (2, 5).  In Crohn’s disease, extended lifespan of T cells 
as well as increased level of pro-inflammatory cytokines such as interferon γ (IFN-γ) and 
tumor necrosis factor α (TNF-α) induces and perpetuates chronic inflammation (6).  In 
the case of transplantation, activation of host T cells would lead to rejection of the 
allografts; therefore, the host immune responses has to be suppressed intentionally (7). 
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Immunotherapies have been explored based on the concept of immune balance (4, 8-
11).  One way to achieve immune modulation is using antibodies to block cell surface 
molecules or neutralize soluble cytokines (12-14).  The emergence of hybridoma 
technology (15) has made production of monoclonal antibodies (mAb) possible at the 
manufacturing scale.  Currently, there are 30 mAb drugs approved by FDA (Table 1-1) 
with more than 400 clinical trials in progress.  Antibodies could modulate the immune 
activity by blocking cell surface molecules, such as CD3, CD20, IL-2 receptor (IL-2R), 
CD33, CTLA-4, and programmed cell death protein 1 (PD1), or by neutralizing pro-
inflammatory cytokines, such as TNF-α.   For instance, the affinity of CTLA-4 to B7 
molecules is 20 times higher than that of CD28 to B7.  The binding of CTLA-4 to B7 
molecules could deliver an inhibitory signal to activated T cells, which help the tumor 
escape from immune surveillance (2).  Ipilimumab binds to CTLA-4 and abolishes the 
competing binding of CTLA-4 to B7 molecules, which results in activation of T cells 
(Figure 1-1). 
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Antibody Trade name Target Indication Approval 
Muromonab-CD3 Orthoclone Okt3 CD3 Kidney transplant rejection 1986 
Abciximab Reopro GPIIb/IIIaR Blood clots in angioplasty 1994 
Rituximab Rituxan CD20 Non-Hodgkin's lymphoma 1997 
Basiliximab Simulect IL2R Kidney transplant rejection 1998 
Daclizumab Zenapax IL2R Kidney transplant rejection 1997 
Palivizumab Synagis AFP RSV infection 1998 
Infliximab Remicade TNF-α Crohn’s disease 1998 
Trastuzumab Herceptin HER2 Breast cancer 1998 
Gemtuzumab Mylotarg CD33 Acute myeloid leukemia 2000 
Alemtuzumab MabCampath CD52 Chronic myeloid leukemia 2001 
Adalimumab Humira TNF-α Rheumatoid arthritis 2002 
Tositumomab Bexxar CD20 Non-Hodgkin lymphoma 2003 
Efalizumab Raptiva CD11a Psoriasis 2003 
Cetuximab Erbitux EGFR Colorectal cancer 2004 
Ibritumomab Zevalin CD20 Non-Hodgkin's lymphoma 2002 
Omalizumab Xolair IgE Asthma 2003 
Bevacizumab Avastin VEGF Colorectal cancer 2004 
Natalizumab Tysabri α4 integrin Multiple sclerosis 2004 
Ranibizumab Lucentis VEGF Macular degeneration 2006 
Panitumumab Vectibix EGFR Colorectal cancer 2006 
Eculizumab Soliris C5 Paroxysmal nocturnal hemoglobinuria 2007 
Certolizumab Cimzia TNF-α Crohn disease 2008 
Golimumab Simponi TNF-α Rheumatoid arthritis and spondylitis 2009 
Canakinumab Ilaris IL1b Muckle-Wells syndrome 2009 
Catumaxomab Removab EpCAM/CD3 Malignant ascites 2009 
Ustekinumab Stelara IL12/23 Psoriasis 2009 
Tocilizumab Actemra IL6R Rheumatoid arthritis 2010 
Ofatumumab Arzerra CD20 Chronic lymphocytic leukemia 2009 
Denosumab Prolia RANK-L Bone Loss 2010 
Belimumab Benlysta BLyS Systemic lupus erythematosus 2011 
Ipilimumab Yervoy CTLA-4 Metastatic melanoma 2011 
Brentuximab Adcetris CD30 Hodgkin lymphoma 2011 
Pertuzumab Perjeta HER2 Breast Cancer 2012 
Raxibacumab Abthrax PA Anthrax infection 2012 
AdoTrastuzumab Kadcyla HER2 Breast cancer 2013 
Obinutuzumab Gazyva CD20 Chronic lymphocytic leukemia 2013 
Ramucirumab NA VEGFR2 Gastric cancer In review 
Vedolizumab NA α4β7 integrin Ulcerative colitis, Crohn’s disease In review 
Siltuximab NA IL-6 Castleman disease In review 
Secukinumab NA IL-17a Immunosuppression In review 
Nivolumab NA PD1 Melanoma In review 
Lambrolizumab NA PD1 Melanoma In review 
Dinutuximab NA GD2 Neuroblastoma In review 
 
Table 1-1 Therapeutic mAb approved or in review.  Information is up to date as of Jan 
4, 2014. Adapted with permission from Janice M. Reichert Ph.D. (Editor-in-Chief, mAbs; 
President, The Antibody Society). GPIIb/IIIaR: glycoprotein IIb/IIIa receptor; IL-2R: IL-
2 receptor; AFP: A antigenic site of the F protein in respiratory syncytial virus; TNF-α: 
tumor necrosis factor alpha; HER2: human epidermal growth factor receptor 2; EGFR: 
epidermal growth factor receptor; IgE: immunoglobulin E; VEGF: vascular endothelial 
growth factor; C5: complement protein C5; EpCAM: epithelial cell adhesion molecule; 
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IL-6R: IL-6 receptor; RANK-L: receptor activator of nuclear factor kappa ligand; BLyS: 
B lymphocyte stimulator; CTLA-4: cytotoxic T lymphocyte antigen-4; PA: protective 
antigen of lethal toxin of Bacillus anthracis; VEGFR2: vascular endothelial growth factor  
receptor 2; PD1: programmed cell death 1; GD2: disialoganglioside 2; RSV: Respiratory 
syncytial virus. 
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Figure 1-1 Therapeutic mechanism of Ipilimumab, an anti-CTLA-4 antibody.  
Normally, T cells are activated after interacting with APCs via MHC-TCR and B7-CD28 
(a). However, T cells also express CTLA-4, which compete for the binding of B7 
molecules and transmit an inhibitory signal (b). When the CTLA-4 is blocked by 
Ipilimumab (c), the activation of T cells is restored.  
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    One of the major obstacles of these approved mAbs therapeutics is poor distribution in 
diseased tissues (16, 17).  Despite their high specificity for targeted antigens, many mAbs 
lack the necessary specificity at the organ/tissue level.  Consequently, off-target binding 
of mAbs in non-diseased tissues or bystander cells can result in severe immune related 
side effects (18).  For example, Ipilimumab, targeting CTLA-4, was developed to restore 
the immune response to cancer cells.  Nonetheless, severe side effects, such as colitis and 
rash, had been reported due to the non-selective blocking of inhibitory signal of T cells in 
normal tissues (19).  Administration of immune suppressive antibodies, such as anti-IL-
2R antibodies, in transplantation management would render the patients vulnerable to 
infections, or even cancer development.  More importantly, this non-specific distribution 
has been a great barrier to the successful development of new mAb.  Teplizumab was 
tested in clinical trials for Type I diabetes.  Binding of Teplizumab to CD3 on T cells 
leads to immune suppression.  The results from clinical trials were disappointing as it 
also increased the risk of infection and cancer development  (20).  
To mitigate these side effects, mAbs can be administrated to the local immune milieu 
(21).  Intratumoral injection is an example of such efforts.  However, researchers have 
shown that mAbs can diffuse away quickly from tumor due to elevated interstitial fluid 
pressure (22) or may be rapidly cleared by Fc receptor mediated endocytosis and 
lymphatic drainage (23).  These barriers continue to impede the long-term success of 
mAb therapeutic development and drive the necessity for the strategic design of an 
effective mAb delivery system to improve the clinical outcomes of mAb therapeutics.  
The goal of my project is to develop a versatile system that could retain antibodies in the 
diseased tissue.  
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Significance 
The global revenue of mAbs reached $44.6 billion in 2011, and it is projected to rise at an 
annual growth rate of 5.3% to about $58 billion in 2016 (24).  Of the 30 mAbs approved 
and several potential ones in development, 25 exert their therapeutic effects by 
modulating immune activity via neutralizing cytokines or binding to cell surface 
molecules (Table 1-1).  The advantageous efficacy of mAbs lies in their excellent 
specificity and high affinity towards their cognate antigens.  However, the therapeutic 
outcomes are compromised due to systemic exposure (12, 13, 16, 18).  This undesirable 
exposure to cells other than target cells causes severe side effects.  To minimize systemic 
exposure, there is a great unmet need for efficient antibody delivery systems. 
    We have developed an antibody delivery system that could stably display antibodies at 
the site of injection for at least 5 days in vivo.  In this system, two peptides, EAK16-II 
and EAKIIH6, co-assemble into a stable His-tagged membrane in situ.  His-tags are 
recognized and bound by anti-His-tag antibodies (dissociation constant (Kd) ~ 2 × 10
-9 M, 
(25)), which also provide Fc domains to protein A/G (pAG).   Hexavalent pAG could 
interact non-covalently with Fc domains of both anti-His-tag antibody and therapeutic 
IgG molecules with high affinity (Kd ~ 1 × 10
-8 M, (26)).  Theoretically, any antibody 
(IgG) could be loaded onto the His-tags via its Fc domain.  The stimuli-responsiveness of 
self-assembling peptides may provide excellent patient compliance in future clinical 
translation.  Peptides and proteins can be mixed and injected using syringes. Upon 
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exposure to physiological salts, the peptides spontaneously self-assemble in situ to 
display antibodies.   
    The His-tagged membrane is considered to be biocompatible. Studies have shown that 
self-assembling peptides are not immunogenic, inflammatory, or cytotoxic.  The Zhang 
group had tested the biocompatibility of EAK16-II in rabbits and rats.  No detectable 
immune response was elicited and no significant titers of antibodies were produced (27, 
28).  Histology studied revealed that no apparent inflammation or any structural 
abnormalities were observed in the muscle tissue where the injection occurred.  Our 
studies had shown that the EAK16-II/EAKIIH6 membrane was not toxic to epithelial 
cells and T cells (unpublished data).  It was found that EAK16-II has similar sequence to 
intermediate neural filament H, L, and M proteins, which may mark them as “self-
molecules” (29).  
    After administration, we expect the system would degrade eventually.  His-tagged 
membrane may first break down into small fragments, which may be taken up by residing 
macrophages or drained into the lymphatic system.  Peptides in macrophage could be 
processed and degraded in lyso-endosomal compartments by enzymatic cleavage.  More 
importantly, single peptide, measures about 6 nm × 1 nm, might further dissociate from 
these fragments and be cleared by renal filtration, which has a size cut off of 10 nm (30).  
    This antibody display system is highly versatile.  First, any IgG molecules may be 
displayed via the non-covalent pAG-Fc interactions.  The antibody display system can be 
transferred and studied in different disease models using antibodies targeting different 
antigens.  Second, coordination bonds between Histidines and metal ions (e.g. Nickel) 
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can be employed to load other therapeutic regimens.  For example, the Meng lab had 
developed and characterized poly(lactic-co-glycolic acid) (PLGA)-polyvinyl alcohol 
(PVA) nanoparticles modified with Nickel-lipids, which provide Nickel ions on 
nanoparticle surface.  Therapeutic agents may be encapsulated into nickel coated 
nanoparticles, which would be stably loaded onto the His-tagged EAK16-II/EAKIIH6 
membrane (data unpublished).  Third, interactions of streptavidin and biotin may be 
employed as linking mechanisms.  EAK16-II may be functionalized with a biotin in the 
C-terminal.   Using streptavidin as a linker, biotinylated antibodies might be displayed 
through the non-covalent biotin-streptavidin interactions.  Fourth, His-tagged peptides 
co-assemble with the parent peptides to form His-tagged membranes in situ.  Thus, other 
self-assembling peptides may be explored to form the His-tagged membrane, which allow 
us to further optimize the performance of antibody display system in different disease 
models by selecting different self-assembling peptides.   
Since this antibody display system utilizes non-covalent interactions between proteins, 
antibodies displayed are unlikely to denature compared to conjugation.  The antigen 
binding domains (Fab) are oriented away from the EAK16-II/EAKIIH6 membrane for 
optimal binding.  When multivalent antigens or cell surface antigens are targeted, the 
apparent binding affinity (avidity) will be increased exponentially as the binding may 
occur at multiple sites simultaneously and synergistically.  For example, single-chain 
antibody fragments (scFv), which has only one binding domain, have a Kd  of 3.2 × 10
-7 
M; the Kd  of the full antibody (two binding domains) plummets to 5 × 10
-10 M (31).  
Cells carry a few hundred to a few thousand copies of a certain surface marker (1), 
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therefore, once bound, the target cell is unlikely to desorb due to this multivalent 
interaction mode (Figure 1-2). 
 
Figure 1-2 Proposed multivalent interactions between displayed antibodies and 
target cell.   
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In our design, two peptides, EAK16-II and EAKIIH6, co-assemble into fibrous 
membrane in situ, with the latter providing antibody loading sites.  An advantage of this 
approach is that the functional motif is structurally decoupled from the assembling 
domain, thereby allowing adjustment of the density of functional motif by simply 
changing the ratio of the two.   Specifically, the dose of antibody displayed could be 
tuned by the His-tag density.  Antibodies are mounted onto His-tags via linker proteins.  
The theoretical maximal antibody dose is determined by the steric effect of IgG 
molecules.  Hydrodynamic dimensions of the antibody were about 25 nm × 4 nm when 
assuming an ellipsoidal shape (32).  According to Ma et al, the distance of two Fab 
domains is 16.9 nm (33), hence, only one αH6-IgG would be bound per 16.9 nm of fibrils. 
In other words, even there are several His-tags present, only one His-tag will be 
apparently accessible per 16.9 nm fibril.  Further reducing the His-tag density (< 1 His-
tag per 17 nm) would render all His-tags accessible to αH6-IgG, allowing precise 
adjustment of the dose of antibodies displayed. 
In addition, characterization of the peptide co-assembly has broader impact in 
functionalization of self-assembling peptides and pathogenesis of β-amyloids in 
neurodegenerative diseases.  Biologically active motifs have been conjugated to self-
assembling peptide to promote the proliferation and differentiation of cells (34).  Like 
EAKIIH6, these functionalized peptides generally lack self-assembling capacity; 
therefore, parent peptides are usually added to form the peptide co-assembly and display 
the functional motifs.  Our data has demonstrated that this strategy (peptide co-assembly) 
is feasible and the density of the functional motifs can be tuned by changing the ratio of 
two peptides.  EAKIIH6 adopts α-helix conformation and could not self-assemble into 
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ordered β-sheet structures.  At the presence of parent peptide β-sheets, EAKIIH6 is able 
to co-assemble possibly by adopting a β-strand conformation as suggested by the “dock 
and lock” theory (35).  This template guided conformational conversion may also exist in 
the formation of β-amyloids.  Native proteins may unfold and become stabilized in β-
strand conformation when there are existing β-sheet templates. 
     In summary, a biocompatible, versatile, and injectable antibody display system have 
been developed and characterized.  The driving motivation is to improve the clinical 
outcomes of immune-modulatory mAb by minimizing systemic exposure.  Immobilized 
antibodies would neutralize soluble antigens, such as TGF-β and TNF-α, or interact with 
immune cells directly by binding to cell surface molecules, such as CTLA-4 and MHC.  
Antibodies will stay at the site of injection for an extended period of time; hence, 
undesirable effects to non-targeted cells would be minimized. 
 
Antibody display system 
The use of self-assembling peptides to construct functional biomaterials has been 
extensively studied in recent years (36, 37).  By manipulating the peptide composition 
(charge, hydrophobicity, and/or number of repeats), functional biomaterials can be 
prepared from simple monomers (37, 38).  A detailed review on ionic complementary 
self-assembling peptides is provided in chapter 2 of this dissertation.  The self-
assembling β-sheet peptide, EAK16-II, represents one of these kinds. EAK16-II 
(sequence: AEAEAKAKAEAEAKAK, E: glutamate; A: alanine; K: lysine) was 
discovered in a yeast protein, which binds to left-handed DNA (Z-DNA) (39).  EAK16-II 
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is composed of alternating hydrophobic (alanine) and hydrophilic (glutamic acid and 
lysine) amino acids.  At neutral pH, EAK16-II adopts a β-strand conformation with 
hydrophobic alanine side chains at one side and hydrophilic glutamate and lysine side 
chains on the other side.  These β-strands align in an anti-parallel manner and form 
amphiphilic β-sheets stabilized by hydrogen bonding among peptide backbones.  The 
addition of salts will effectively screen ionic charges.  Therefore, upon salt exposure (> 
20 mM), these β-sheets laminate into nanofibers by inter-sheet hydrogen bonding and 
electrostatic interactions and inter-sheet hydrophobic interactions (Figure 1-3).  This is 
thermodynamically favorable because water molecules hydrating hydrophobic alanines 
are released (entropy increase).  The physical crosslinking of these nanofibers produces a 
stable gel-like structure (40, 41).  Replacing alanine, glutamate, or lysine with similar 
amino acids does not change the self-assembling capacity (42), and therefore, a series of 
self-assembling β-sheet peptides have been designed and characterized including 
RADA16-II (sequence: (RARADADA)2, R: arginine; D: aspartate) (43). 
 
Figure 1-3 Schematic depiction of the self-assembling of EAK16-II.  Figure adapted 
with permissions from reference (38) and (42). 
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    Self-assembling peptides have been widely investigated as delivery systems.  
Antibodies and growth factors are all capable of being loaded and delivered using the gel 
in situ.  The molecular weight and surface charge of the macromolecules and nanofiber 
density of the gel dictate the release profile (44-46).  Alternatively, short bioactive 
peptides were conjugated to the C-termini by peptide bonds (47-49).  Although the 
addition of functional group impaired the self-assembling capacity, the modified peptides 
could co-assemble with the parent peptides to display the functional motifs (47-49).  
These studies, among others, confirm the feasibility of using self-assembling peptides for 
antibody delivery. 
To utilize EAK16-II for local delivery of IgG molecules, several possible strategies 
can be considered.  Firstly, IgG can be encapsulated into the fibrous networks non-
specifically (44). However, orientation of the IgG cannot be guaranteed.  In addition, IgG 
will still be cleared rapidly after they diffuse out of the EAK16-II structure.  The second 
strategy is to covalently conjugate the IgG molecules onto EAK16-II either by chemical 
synthesis or protein expression.  Besides the tedious efforts involved in conjugation, the 
bulky IgG may completely abolish the self-assembling capacity (34).  The third strategy 
is tethering IgG onto the EAK16-II membrane by non-covalent but specific interactions; 
however, there are no mounting sites on EAK16-II to serve for this purpose.  In order to 
design a versatile platform for local delivery of mAb, we functionalized EAK16-II with a 
His-tag appended at the C-terminus, i.e. EAKIIH6 (sequence: 
AEAEAKAKAEAEAKAK-HHHHHH, H: histidines) (50) (Figure 1-4).  EAK16-II and 
EAKIIH6 co-assemble into an insoluble fibrous network with the His-tag accessible. 
Anti-His-tag antibodies (αH6-IgG) and protein A/G (pAG) are utilized as intermediate 
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adaptors (Figure 1-5).  αH6-IgG binds to the His-tags with its Fab domains, and provides 
Fc domain for the recognition of pAG. pAG has six binding sites for Fc domains (51).  
Therefore, a second IgG can be displayed via its Fc domain, and can orient the Fab 
domains away from the surface because of the steric effects of IgG molecules.  IgG 
molecules (MW 150 kDa) are much larger than pAG (MW 50 kDa).    When a second 
IgG molecule approaches the pAG already bound to αH6-IgG, it would locate itself away 
from αH6-IgG as far as possible to minimize steric repulsion.  This favorable orientation 
of Fab domains would facilitate the binding to cognate antigens.  Peptides and antibodies 
can be injected as a solution into physiological conditions to display IgG as the peptides 
self-assemble in situ.  Antibodies displayed are unlikely to denature due to a lack of 
covalent conjugation.  We also envision that the dose of antibodies can be adjusted by 
tuning the number of available loading sites, i.e. His-tags.  Our long term goal is to 
develop this antibody display system as a versatile platform for immune modulation.  The 
system was shown to remain stable in vitro for 7 days in PBS.  When anti-CD4 
antibodies were mounted, CD4 T cells were captured from a mixed population of 
lymphocytes (52).  However, the performance has not been tested and validated in vivo.   
How the two peptides co-assemble warrants closer examination. 
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Figure 1-4 Peptide sequence and chemical structures of EAK16-II and EAKIIH6.   
Schematic illustration was drawn in Molecular Operating Environment with peptides in 
extended form. Red: oxygen; blue: amine: gray: carbon; light gray: hydrogen. 
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Figure 1-5 Schematic illustration of the peptide co-assembly and antibody display 
system.  EAK16-II and EAKIIH6 co-assemble into a fibrous structure to provide 
accessible His-tags. αH6-IgG binds to those His-tags and pAG binds to the Fc of αH6-
IgG. Through Fc-pAG interactions, any IgG molecules can be loaded. Molecular models 
of IgG were generated from the x-ray structure of an IgG2a antibody (PDB entry 1IGT 
(53)) using Jmol. 
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A prototype formulation had been developed for proof-of-concept studies based on 
pilot experiments.  EAK16-II is mixed with EAKIIH6 at a molar ratio of 4:1.  In a second 
vial, αH6-IgG, therapeutic IgG, and pAG are mixed at a molar ratio of 2:2:1 to form the 
αH6-IgG/pAG/therapeutic IgG complexes through Fc-pAG interactions.  The molar 
ratios of EAK16-II/EAKIIH6/αH6-IgG/pAG/therapeutic IgG are 9292:2273:2:2:1 and the 
molar ratio of His’s-tag to αH6-IgG is 1136:1.  These two vials are withdrawn into the 
same syringe and injected immediately.  The rationale for excessive self-assembling 
peptides is that all antibodies would be displayed, which is proved to be true after 2 h 
incubation in vitro (Figure 3-3, lane II).  In this dissertation, The performance of this 
formulation had been investigated in vitro and in vivo. 
Component 
M.W. 
(Da) 
Concentration 
(µg/µL) 
Amount used 
(µL) 
Moles used 
(µmol) 
Molar 
ratio 
EAK16-II 1656 5 20 0.06 9292 
EAKIIH6 2480 7.5 5 0.015 2273 
αH6-IgG 150,000 0.2 10 1.33 × 10-5 2 
Therapeutic 
IgG 150,000 0.2 10 1.33 × 10-5 2 
pAG 50,000 0.25 1.5 6.5 × 10-6 1 
 
Table 1-2 Stoichiometry of the antibody display system.   
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Project overview 
The purpose of my dissertation work is to demonstrate the feasibility and performance of 
antibody display system (EAK16-II/EAKIIH6/αH6-IgG/pAG/therapeutic IgG).  The 
central hypothesis of this project is that immune activity can be modulated through 
antibodies displayed on in situ forming peptide co-assembly.  To test this hypothesis, 
three specific aims were proposed and studied.   
In aim 1, proof-of-concept characterization of the antibody display system was 
performed (chapter 3).  Our gel electrophoresis data demonstrated that antibodies are 
displayed onto the His-tags specifically through the linker proteins, αH6-IgG and pAG.  
Under scanning electronic microscopy (SEM), the IgG-pAG complexes were found to be 
evenly distributed on EAK16-II/EAKIIH6 fibrils. The dimensions of these complexes 
indicate most His-tags display one therapeutic IgG molecule.  Using TGF-β as the model 
antigen, the anti-TGF-β antibodies displayed remained biologically active, and were able 
to bind to its cognate antigen from three different sources in two experimental settings.  
Upon administration into mice subcutaneously, the self-assembling peptides co-
assembled into stable His-tagged membrane up to 11 days locally.  More importantly, the 
antibody display system could retain a fluorescent dye labeled IgG in two epithelial 
tumors in vivo.   IgG co-administrated with the system were found to remain in 4T1 
mouse mammary tumors for up to 120 h, while free IgG was cleared within the first 24 h.   
Decreased clearance was also found in B16 melanoma established in mouse footpads.  In 
addition, the system was able to deliver antibodies to the entire tumor tissue.  These 
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studies prove that the antibody display system is effective in retaining antibodies locally 
in vivo. 
In aim 2, the biological performance of the antibody display system to modulate 
immune activity was investigated in a mouse skin transplantation model (chapter 4).   In 
this model, host T cells are activated by direct allorecognition of emigrating donor 
antigen presenting cells (dAPCs) (7, 54).  These host T cells will mediate acute rejection 
shortly after the surgery, which dictates outcome of surgery.  The working hypothesis is 
that displayed anti-dAPC antibodies can impede the trafficking of dAPCs to attenuate 
systemic T cell response.  The EAK16-II/EAKIIH6 membranes loaded with antibodies 
were found to remain underneath normal and grafted skins for up to 6 days.  dAPCs were 
targeted using an antibody that binds to the MHC-II molecule expressed exclusively by 
donor cells.  In mice treated with the anti-dAPC membrane, fewer dAPCs were found in 
host draining lymph nodes.  T cells from these recipient mice produced lower 
concentrations of IFN-γ after being cultured ex vivo with dAPCs.  These data suggest that 
the antibody display system has the potential to alter the immune activity in vivo. 
    In aim 3, we sought to understand the EAK16-II/EAKIIH6 co-assembly (chapter 5).  
The working hypothesis is that EAKIIH6 is incorporated into the peptide co-assembly by 
aligning with EAK16-II β-sheets.  We have experimentally investigated the peptide co-
assembly (parent peptide and functionalized peptide).  Native gel electrophoresis 
indicates that EAKIIH6 self-sorted into high molecular weight aggregates without 
EAK16-II.  However, the EAKIIH6 aggregates contained a mixture of α-helices and β-
strands instead of ordered β-sheets structures suggested by FT-IR and circular dichroism 
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(CD) studies.  The self-sorting of EAKIIH6 was inhibited by the parent peptide in a 
concentration dependent manner.  Comparing the co-assembly efficiency of EAKIIH6 to 
two control peptides implies that EAKIIH6 adopted β-strand conformation and aligned 
with existing amphiphilic EAK16-II β-sheets for incorporation.  Injecting solutions of 
EAK16-II and EAKIIH6 subcutaneously rendered His-tags detectable in live mice for at 
least 312 h despite at a diluted concentration for EAKIIH6.  It was also found that the 
accessibility of His-tags depended on the ratio of the two both in vitro and in vivo.  These 
studies demonstrated that EAKIIH6 co-assembles with EAK16-II and the His-tag density 
is tunable by changing the ratio of the two. 
To conclude, the central hypothesis has been validated.  Antibodies could be stably 
displayed onto the EAK16-II/EAKIIH6 membrane via intermediate proteins, αH6-IgG 
and pAG, both in vitro and in vivo.  The trafficking of dAPCs to draining lymph nodes 
was impeded by the anti-dAPC membrane, which resulted in attenuated host T cell 
activity.  EAKIIH6 was incorporated into the EAK16-II β-sheets and the density of His-
tag could be tuned by changing the ratio of the peptides.  These data indicate that the 
antibody display system is effective and promising.  It can be utilized as a local antibody 
delivery system for antibodies targeting soluble antigens as well as an in situ forming 
membrane/surface to display antibodies targeting cell surface molecules to immobilize 
target cells.   
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CHAPTER 2  
Design, Mechanisms, and Applications of Ionic Complementary β-sheet 
Self-Assembling Peptides 
Abstract 
Ionic complementary β-sheet self-assembling peptides represent a major class of 
biomaterials in tissue engineering and drug delivery.  Upon exposure to stimuli, these 
peptides self-assemble into nanofibers, stabilized by H-bonding, electrostatic interactions, 
and hydrophobic interactions involving both the peptide backbones and side chains.  This 
provides a “bottom-up” approach in designing nanoscale biomaterials.  By manipulating 
the peptide composition and concentration, distinctive macroscopic structures can be 
obtained for different applications.  These peptides offer advantages of biocompatibility 
and stimuli-responsiveness.  In this chapter, the design, mechanisms, and applications of 
self-assembling ionic complementary peptides are reviewed.  
 
Introduction 
Molecular self-assembly refers to the spontaneous assembly of molecules into highly 
ordered structures through non-covalent interactions, such as H-bonding, hydrophobic 
interactions, and electrostatic interactions (38).  It is a sophisticated and delicate balance 
both thermodynamically and kinetically.  Molecular self-assembly serves as a great 
“bottom-up” approach to design and develop nanoscale biomaterials for tissue 
engineering and regeneration, cell culture, and drug delivery (36, 55).  Ionic 
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complementary β-sheet based self-assembling peptides represent one of these kinds.  
These self-assembling peptides share a common sequence feature (XZXZ)n, wherein X is 
a hydrophobic amino acid and Z is a hydrophilic amino acid (37).  EAK16-II (sequence: 
AEAEAKAKAEAEAKAK; A: alanine; E: glutamic acid; K: lysine), a natural sequence 
in Zuotin, is the first ionic complementary self-assembling peptide discovered (56-58).  
Thereafter, a series of self-assembling peptides have been developed by manipulating the 
sequence, amino acid residues, and number of repeats in EAK16-II.  These peptides self-
assemble into three dimensional fibrillar networks in response to stimuli.  The self-
assembly is determined by many factors, such as peptide concentration, salt, pH, and 
temperature.  However, no conclusive mechanism and process of self-assembly have 
been reported.  
Short self-assembling peptides offer several advantages. Unlike proteins, they can be 
produced at a large scale through solid phase peptide synthesis, and composition can be 
modified easily.  They are considered as non-immunogenic insofar as no high titer 
antibodies have been detected in animal studies (27, 28).  Therefore, explosive effects 
have been invested to develop β-sheet based self-assembling peptides for a variety of 
purposes. 
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Self-assembly of ionic complementary peptides 
Rational design of self-assembling peptides 
EAK16-II has alternating hydrophobic amino acid residues and hydrophilic amino acid 
residues.  When β-strand conformation is adopted, EAK16-II has a distinctive 
amphiphilic pattern with all hydrophobic alanine side chains on one side and all 
hydrophilic lysine and glutamate side chains on the other side (Figure 2-1).  At neutral 
pH, glutamic acid is deprotonated (pKa = 4.2) and lysine is protonated (pKa = 10.7).  
Therefore, EAK16-II has a characteristic charge pattern of “--++--++”.  Shortly after the 
discovery of EAK16-II, a series of self-assembling peptides have been designed by 
systematically modifying the order, number, and type of amino acid residues (59) (Table 
2-1).  For example, EAK16-I (AEAKAEAKAEAKAEAK) and EAK16-IV 
(AEAEAEAEAKAKAKAK) was designed by adjusting the order of amino acid residues 
in EAK16-II.  The RADA series were developed by replacing glutamic acid with aspartic 
acid (D) and replacing lysine with arginine (R).  These ionic complementary peptides 
have been classified into four moduli based on charge distribution: modulus I (-+-+-+-+); 
modulus II (--++--++); modulus III (---+++); modulus IV (----++++) (59).  The roman 
numerals indicate the number of same charge grouped together. The name also includes 
information on type (single amino acid code) and total number of amino acid residues.  
For example, EAK16-II consists of a total of 16 amino acid residues of glutamic acid (E), 
lysine (K), and alanine (A). The charge distribution pattern is modulus II (--++--++). 
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Figure 2-1 EAK16-II peptide in β-strand conformation.  Red: oxygen; blue: amine; 
gray: carbon; light gray: hydrogen. 
 
 
Peptide Sequence Charge pattern Reference 
EAK16-I AEAKAEAKAEAKAEAK -+-+-+-+ (60) 
EAK16-II AEAEAKAKAEAEAKAK --++--++ (57) 
EAK16-IV AEAEAEAEAKAKAKAK ----++++ (60) 
RADA16-I RADARADARADARADA -+-+-+-+ (61) 
RADA16-II RARADADARARADADA --++--++ (27) 
RADA16-
IV 
RARARARADADADADA ----++++ (59) 
FKFE8-I FKFEFKFE +-+- (62) 
FKFE12-I FKFEFKFEFKFE +-+-+- (62) 
FKFE16-I FKFEFKFEFKFEFKFE +-+-+-+- (62) 
FEFK16-II FEFEFKFKFEFEFKFK --++--++ (63) 
DAR16-IV ADADADADARARARAR ----++++ (64) 
KLDL12-I KLDLKLDLKLDL +-+-+- (65) 
EAR8-II AEAEARAR --++ (66) 
 
Table 2-1 Summary of self-assembling peptides studied.  
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Effect of peptide composition on self-assembly 
The peptide composition, i.e. order, number, and type of amino acid residues, is critical to 
the self-assembling capacity.  Caplan et al studied the effect of peptide composition on 
self-assembly by systematically varying the composition of FKFE12-I 
(FKFEFKFEFKFE) (62).  Specifically, the authors investigated how different 
hydrophobic amino acid residues and number of repeats affect minimal salt concentration 
(critical coagulation concentration) needed to induce self-assembly (gelation).  The 
gelation was monitored by rheological studies.  Increasing the hydrophobicity of the 
nonpolar residues reduced the salt concentration required for self-assembly.  It was 
postulated that self-assembly is favored because higher hydrophobicity produced higher 
entropic compensation than being unassembled.  It has also been reported that alanine-
containing amphiphilic peptides (such as EAK) require at least sixteen-mer peptides for 
salt-induced stable matrix formation.  By contrast, leucine-containing amphiphilic 
peptides (such as ELK) form salt-induced stable matrices from eight-mer peptides (61).  
Self-assembly does not require the same hydrophobic residues throughout the peptide.  
Wang et al replaced some or all of the phenylalanine (F) in FEFK16-II 
(FEFEFKFKFEFEFKFK) with different amino acids (Table 2-2) (63).  The steric effects 
did affect the formation of matrix when different sizes of hydrophobic side chains could 
not accommodate each other (Figure 2-2).  However, hydrophobic side chains would fit 
with each other by sliding when hydrophobic residues were located in a certain pattern.  
For example, self-assembly was preserved when large hydrophobic residues were 
distributed in the middle or the ends.  
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Table 2-2 Sequences of the amphiphilic peptides studied.   Adapted with permission 
from reference (63). 
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Figure 2-2 Schematic representation of cooperative hydrophobic interactions among 
hydrophobic residues of different sizes.   Peptide 81 and 82a were able to self-assemble 
because hydrophobic side chains could accommodate with each other.  The self-assembly 
of peptide 83 was abolished as hydrophobic interactions were disrupted.  Adapted with 
permission from reference (63). 
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    Charge distribution also plays a role in self-assembly.  The self-assembly of three 
EAK16 peptides, namely, EAK16-I, EAK16-II and EAK16-IV, had been investigated by 
AFM and surface tension measurements (60, 67).  At neutral pH, EAK16-I and EAK16-II 
adopted a β-sheet conformation and formed fibrillar structure.  However, EAK16-IV 
favored a β-turn conformation and formed globular structure.  EAK16-IV has a charge 
pattern of “----++++”, therefore, the peptide may bend (β-turn) due to intramolecular 
electrostatic interactions (67).  In addition, peptides have a higher propensity to self-
assemble when peptides are electrically neutral (68).  This explains why higher salt 
concentration was needed for assembly when glutamic acids were replaced by glutamine 
(63).  The net positive charges imposed by lysine have to be screened by higher 
concentration of salts. 
The peptide length exerts a biphasic effect on self-assembly.  For example, FKFE12-I 
requires lowest concentration of salt for assembly while FKFE8-I and FKFE16-I require 
a higher salt concentration (62).  Self-assembly is a delicate thermodynamic balance.  
Increasing the length of peptide may strengthen the intermolecular interactions as the 
number/extent of H-bonding, electrostatic interactions, and/or hydrophobic interactions 
increase (enthalpy).  However, the entropy loss contradicts these as the peptide has to 
adopt a certain conformation during assembly.  
Using chiral counterpart D-amino acids does not abolish the self-assembly.  Since the 
D-peptide cannot be recognized by natural proteases, self-assembling peptides of D-
amino acids may produce more stable scaffolds (69, 70). 
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Effect of salts on self-assembly 
Salts trigger self-assembly by screening repulsive net charges of peptides.  Hong et al 
found that the self-assembly of EAK16-II did not strongly depend on the presence of 
NaCl at higher peptide concentration (>0.3 mg/mL) (71).  However, the dimensions of 
self-assembled nanofibers appeared to be dependent on NaCl concentration at low 
peptide concentrations (<0.1 mg/mL) (71).  Globular assemblies were observed in the 
absence of NaCl at low peptide concentration.  The radius of the nanofibers increased 
until NaCl reached about 20 mM.  Further increasing salt concentration resulted in 
smaller nanofibers.  This indicates that NaCl promotes formation of fibril at low peptide 
concentration (71).  Zhang and coworkers studied the effects of different salts on self-
assembly of EAK16-II (57).  Monovalent cations triggered assembly formation 
effectively, while divalent cations induced disordered aggregation.  The order of 
effectiveness had been determined as Li+ > Na+ > K+ > Cs+, which corresponds to the 
hydrated radius of the ions: 3.40 Å (Li+), 2.76 Å (Na+), 2.32 Å (K+) and 2.28 Å (Cs+).  In 
addition, organic cations, such as NH4
+ and TrisH+, were not able to induce EAK to form 
aggregates (57).  However, the effects of salts on different peptides differ.  Caplan et al 
demonstrated that multimeric ions were more effective in triggering self-assembly of 
FKFE12-I at pH 3 with the order of K3Fe(CN)6 > K2SO4 > KCl. At pH 3, FKFE12-I 
carries net positive charges as glutamic acids are neutralized. The charge screening effect 
is then dependent on the valence of negative ions.  Hence, the role of salts in peptide 
assembly warrants more examination. 
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Effect of peptide concentration on self-assembly 
The Chen group reported a critical self-assembly concentration (CSAC) of 0.1 mg/mL 
(60 μM) for EAK16-II in pure water (71, 72).  Surface tension and dimensions of 
nanostructures were determined for a wide range of peptide concentrations using 
axisymmetric drop shape analysis-profile (ADSA-P) and atomic force microscopy (AFM) 
respectively, which correlated with each other very well.  Surface tension dropped to 
minimal when the peptide self-assembled at 0.1 mg/mL. Under AFM, fibrillar networks 
were observed above the CSAC, while only isolated filaments appeared at concentrations 
below the CSAC.  Nonetheless, whether the mica surface used in AFM had any effect on 
peptide assembly remains an open question. 
 
Effect of pH on self-assembly 
Although pH affects the protonation/de-protonation state of ionizable side chains of 
amino acid residues, some peptides are insensitive to pH changes.  For example, EAK16-
II was able to self-assemble into nanofibers from pH 1.5 to 11.  This is not unexpected.  
In addition to the charge screening effect of salts (58), hydrogen-bonding among side 
chains of glutamate and lysine could also stabilize the fibrils.  Ye et al reported that 
RADA16-I self-assembled into fibrillar structures in acidic pH but not in basic pH (43).  
But it shall be noted that a lower concentration (0.17 mg/mL) was used and no salts were 
added in Ye’s studies.   On the other hand, EAK16-IV could not form fibrillar structures 
at pH 7 as it adopted a β-turn conformation (67).  
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Mechanism and hierarchy of self-assembly 
In solution state, self-assembling peptides adopt a β-strand conformation.  The 
hydrophobic side is caged within ordered water molecules.  Triggered by charge 
screening effect of salts, the self-assembly is a thermodynamic process driven by entropic 
release of water molecules hydrating hydrophobic amino acid residues. Increasing the 
hydrophobicity of amino acid residues elevates the self-assembling propensity.  Zhang 
and co-workers proposed that peptides align with each other in an anti-parallel manner to 
form amphiphilic β-sheets.  These β-sheets are stabilized by inter-peptide H-bonding 
involving peptide bonds.  Amphiphilic β-sheets stack together and form nanofibers by 
hydrophobic interactions between hydrophobic faces and H-bonding and electrostatic 
interactions between hydrophilic faces (36, 38, 57) (Figure 1-3).  However, dimensions of 
nanofibers from AFM measurements do not support this model.  The Chen group 
reported a height of about 0.5 nm, which corresponds to the height of a single layer of β-
sheet, for fibrils of EAK16-II formed at 0.1 mg/mL (67).  Although the concentration is 
relatively low compared to those used in Zhang’s studies, it does imply that the self-
assembly process warrants more investigation. 
Cormier and coworkers explored the structure of RADA16-I nanofibers extensively 
using solid state nuclear magnetic resonance (NMR) spectroscopy (73-75).  Solid state 
NMR spectroscopy is extremely useful in studying structures of peptide samples as it can 
pinpoint the conformation of a single amino acid residue, especially when combined with 
isotope labeling (76).  Indeed, the results revealed that RADA16-I peptides are aligned in 
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a parallel manner when forming the β-sheets.  Each peptide shifts a little for maximal 
electrostatic interactions. Two amphiphilic β-sheets stack by hydrophobic interactions 
and the nanofiber grows by attaching peptides at the ends of β-sheets instead of stacking 
more amphiphilic β-sheets (Figure 2-3) (75).  This model correlates well with 
experimental data and computational simulation. The height of nanofibers was measured 
to be 1.5 nm in AFM.  
 
Figure 2-3 Molecular model of RADA16-I assembly.  Peptide backbones are rendered 
as ribbons, and atoms shown for alanine (green), arginine (blue), and aspartate (red) 
residues. (a) Three-dimensional representation of the RADA16-I nanofiber; (b) 
orthographic projection of the hydrophilic surface of a β-sheet, highlighting the predicted 
configuration of arginine and aspartate side chains; (c) orthographic projection of the 
nanofiber cross section. Figure adapted with permission from reference (75). Copyright 
(2013) American Chemical Society. 
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    Interestingly, fibrillar scaffold of ionic self-complementary peptides could reassemble 
after mechanical breakage.  Hammond et al broke RADA16-I nanofibers into short 
fragments with sonication.  The dynamic reassembly was monitored using AFM. The 
fragments were able to reassemble into nanofibers which were indistinguishable from the 
original self-assembly (77, 78).  Yokoi et al proposed a sliding diffusion model to explain 
this dynamic reassembly phenomenon (77).  Sonication broke nanofibers into small 
fragments with protruding ends, which exposed the hydrophobic alanines. Hydrophobic 
interactions draw these fragments together.  These fragments would then slide until a 
perfect fit to minimize the exposure of hydrophobic alanines.  This feature is of great 
value because the self-assembly scaffold will be subject to certain mechanical disruptions 
when applied in in vitro or in vivo environments.  It also implies that scaffold may be pre-
assembled in the syringe.  The shear forces may break down the scaffold but it will 
reassemble at the site of injection. 
 
Applications of ionic complementary self-assembling peptides 
A major concern with novel biomaterials is immunogenicity, proinflammatory, and 
toxicity.  Zhang et al attempted to detect antibodies against RADA16-II and EAK16-II.  
Peptides were injected into rabbits alone or conjugated with other proteins.  No detectable 
immune response was elicited, and no significant titers of antibodies were produced (27).   
It was found that these peptides have similar amino acid sequence to intermediate neural 
filament H, L and M proteins (29).   These sequence similarities mark them as “self-
molecules”, therefore no immune responses are stimulated. Holmes et al injected 
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EAK16-II, RADA16-I, RADA16-II peptides into the rats leg muscles (28).  The entire 
muscle was dissected and sectioned 9 days or 5 weeks after the injections.  The muscle 
sections were examined for mononuclear cell infiltration and muscle fiber necrosis, i.e. 
inflammation or necrosis.  No apparent inflammation or any structural abnormalities were 
observed in the muscles compared to those injected with saline solutions.   These studies 
support the notion that these self-assembling peptides are non-immunogenic and non-
inflammatory. 
Because of the biocompatibility and stimuli responsiveness, self-assembling peptides 
have been widely employed in tissue engineering and regeneration, drug delivery, and 
other medical applications (42, 79, 80). Self-assembling peptides form networks 
spontaneously under physiological conditions.  The networks contain physically cross 
linked nanofibers with a diameter of around a few nanometers and a length up to the scale 
of µm (36).  The pore sizes range from a few nanometers to several micrometers, which 
depends on the peptide concentration. Cells or therapeutic agents are all capable of being 
encapsulated into the network (81). 
 
Tissue engineering and regeneration 
The extracellular matrix (ECM) is a cross-linked network of proteins and carbohydrates, 
which provide structural and biochemical support for cells (82).  Soon after the discovery 
of EAK16-II, Zhang and co-workers found that several types of mammalian cells could 
attach to the fibrillar matrix of EAK16-II or RADA16-II (27).  Thereafter, self-
assembling peptides have been widely explored as cell scaffold in tissue engineering and 
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regenerations (42, 79, 83).  Although the purpose of my dissertation project is to develop 
an antibody delivery system using EAK16-II, applications of self-assembling peptides in 
tissue engineering and regeneration provide important references regarding 
functionalization, biocompatibility, and optimization.  Peptides can be functionalized 
with growth factors and cytokines to direct cell differentiation and growth.  
Biocompatibility had been demonstrated in animals.  Peptidic scaffolds could be prepared 
to better mimic ECM by adjusting peptide composition and concentration.  Indeed, 
RADA16-I has been commercialized as cell culture scaffolds (PuraMatrix, 3-D Matrix, 
Cambridge, MA).  
Sieminski et al compared the adhesion of human umbilical vein endothelial cells 
(HUVEC) to four different self-assembling peptide hydrogels (65).  HUVEC cultured in 
RADA16-I or RADA16-II hydrogels expanded into interconnected capillary-like 
networks, while HUVEC in FKFE8-I or KLDL12-I formed clusters and retained their 
round shape.  RADA16-I and RADA16-II hydrogels were also found to support neutrite 
growth and active synapse formation when sympathetic neurons were cultured (28).  In 
addition, RADA16-I scaffold enhanced dopaminergic differentiation of murine 
pluripotent stem cells (84).  Interestingly, KLDL12-I was able to support the ECM 
production and division of chondrocyte (85).  It has been reported that cells can recognize 
and respond to the stiffness of substrate (86, 87), which may explain why KLDL12-I 
could support chondrocyte but not HUVEC.  
Akiyama and coworkers utilized RADA-I hydrogel to regenerate middle ear mucosa in 
rat (88).  Middle ear epithelial cells were cultured from donor rats and encapsulated in 
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0.25% w/v RADA16-I hydrogel (PuraMatrix) with a density of 0.5 or 1 million/mL.  The 
scaffold with cells was then transplanted into recipient rats, the middle ear of which had 
been surgically removed.  With the RADA16-I scaffold, cells in the subepithelial lesion 
retained their morphology and function.  More importantly, new epithelial and 
subepithelial layers had formed (88).   
Self-assembling peptides have been covalently functionalized with bioactive motifs to 
enhance the proliferation and differentiation of cells.  These bioactive peptide sequences 
can be chemically attached via peptide bonds by solid phase synthesis.  However, the 
self-assembly of functionalized peptides may be compromised, which depends on the 
charge and size of bioactive motif (34).  To circumvent it, functionalized peptides could 
be premixed the parent peptide to form the scaffold together.   Horii et al modified 
RADA16-I with one of the following sequences, osteogeic growth peptide ALK 
(ALKRQGRTLYGF), osteopontin cell adhesion motif DGR (DGRGDSVAYG), and 
RGD binding sequence PGR (PRGDSGYRGDS) (34).  The three modified peptides 
(1:1:1) co-assembled with RADA16-I into a hydrogel matrix displaying the three 
bioactive motif, which promoted the proliferation, differentiation and migration of 
osteoblast (Figure 2-4).  To enhance the adhesion of human aortic endothelial cells, 
sequences in laminin 1 and collagen IV, two constituent peptides of ECM, were 
conjugated to RADA16-I (47).  In another example, Cunha et al attached RGD peptide 
(Arg-Gly-Asp) and bone marrow homing peptides (BMHP) to RADA16-I (48).  Neural 
stem cells proliferated and differentiated in the peptidic scaffold.   
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Figure 2-4 Molecular models of functionalized peptides and peptide co-assembly.    
Functionalized peptides (a) co-assemble with the parent peptide to display biological 
motifs (b). Adapted with permission from reference (34). 
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Stevenson et al investigated the effect of stiffness and binding site density on 
microvascular formation (89).  The ratio of two self-assembling peptides (FKFE8-1 and 
RGD-FKFE8-I) was adjusted to generate scaffold with different stiffness and 
adhesiveness.  A higher content of unmodified FKFE8-I peptides produced stiffer gels 
with less binding sites, in which formation of microvascular network was highly 
compromised (89).  Other functionalization includes RADA16-I with laminin derived 
peptide IKVAV for embryonic stem cells (90), LDLK12-I with peptide KLPGWSG for 
neural stem cells, and RADA16-I with heparin binding motif FHRRIKA for human 
adipose stem cells (91). 
 
Drug delivery 
Zhang and coworkers studied the release profile of four proteins from RADA16-I 
hydrogel scaffold (Figure 2-5) (45).  A biphasic diffusion profile was observed.  A rapid 
initial release following Fick’s law was observed possibly due to proteins at the 
peripheries and those able to diffuse via large pores (Figure 2-5b insert).  After that, 
diffusion deviated from the initial straight line possibly due to hindrance by small pores 
and interactions.  The release was sustained for about 30-50 h.  The release profile 
correlates well with the protein molecule weight.  Diffusion constants were obtained by 
modeling the initial release data with Fick’s law.  Lysozyme, Trypsin inhibitor, bovine 
serum albumin (BSA), and IgG which have molecular weight of 14.3 kDa, 20.1 kDa, 
66.0 kDa, and 150 kDa respectively had an apparent diffusion constant of 0.5 × 10-10 m2/s, 
0.32 × 10-10 m2/s, 0.24 × 10-10 m2/s, 0.07 × 10-10 m2/s accordingly (45).  Kopesky et al 
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studied the release kinetics of transforming growth factor β1 (TGF-β1) from KLDL12-I 
hydrogel (92).  When TGF-β1 (100 ng/mL) was mixed with peptide solution (0.35% w/v, 
50 µL) prior to gelation, over 85% TGF-β1 was encapsulated, compared to 17% for 
agarose gel.  After 21 days of release, KLDL12-I hydrogel released 44% of TGF-β1 
while agarose gel had released 82%.  The release profile could be adjusted by changing 
peptide concentration.  Forming hydrogels at higher peptide concentration produces 
denser networks with smaller pores, which retard and reduce the release (45).   
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Figure 2-5 Graphic representation and release profiles of lysozyme, trypsin 
inhibitor, BSA, and IgG in 1% (w/v) RADA16-I hydrogels.  Four proteins (a) with 
different sizes were studied for their release (b) from RADA16-I hydrogels. Inserted is 
protein release plotted as a function of the square root of time showing biphasic diffusion 
mechanism. Adapted with permission from reference (45). Copyright (2009) National 
Academy of Science, USA. 
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    Positive or negative charges can be introduced into the hydrogel to tune the release 
(93).  Gelain et al attached short amino acid sequence to the C-terminal of RADA16-I.  
The modified peptides, RADA16-DGE and RADA16-PFS, retained the self-assembling 
capacity.   RADA16-DGE formed hydrogel scaffolds with net negative charges while 
RADA16-PFS assembled into networks with net positive charges at neutral pH.  When 
proteins carrying different charges were loaded, the release was dictated by both the 
charges and molecular weights.  The diffusion was highly compromised when proteins 
carry opposite charges to the hydrogel due to attractive electrostatic interactions (93).  
Other attempt includes using a double layer hydrogel of two different self-assembling 
peptides for controlled release of human antibodies.  Koutsopoulos et al formulated an 
“onion-like” hydrogel with RADA16-I as the inner core and KLDL12-I as the outside 
shell (94).  Antibodies were loaded into the inner RADA16-I gel and then coated with 
KLDL12-I hydrogel.  Extended release for over 3 months was demonstrated because of 
the different density and chemical properties between RADA16-I and KLDL-12 
hydrogels.  
Besides direct encapsulation via non-specific encapsulation, another way to deliver 
active proteins is tethering (95, 96).  Both insulin growth factor-1 (IGF-1) and RADA16-
1 were biotinylated. Biotinylated RADA16-1 and RADA16-1 at a ratio of 1:100 
assembled into a hydrogel scaffold with accessible biotins.  Streptavidin was premixed 
with biotinylated IGF-1 at a ratio of 1:1.  Therefore, IGF-1 was loaded onto the 
RADA16-1 nanofibers through the tethering of streptavidin-biotin interactions (Figure 2-
6) (96).  Sustained IGF-1 delivery was observed in rat myocardium for 28 days, and cell 
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implantation efficacy was improved (96).  Similar approach was demonstrated using the 
self-assembling peptide KLDL12-1 (95). 
 
Figure 2-6 Tethering of biotinylated IGF-1 to biotinylated self-assembling peptides 
via biotin-streptavidin interactions.  Red dot: biotin; green square: streptavidin. 
Adapted with permission from reference (96). Copyright (2006) National Academy of 
Science, USA. 
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Systemic delivery using the self-assembling peptide KLDL12-I has also been reported 
(97). Polyethylene glycol (PEG) was conjugated to KLDL12-I through a short peptidic 
linker.  This modified peptide self-assembles into single layer nanofibers of 4 nm in 
width and 50-400 nm in length.  These nanofibers exhibited desirable properties of non-
toxicity, hemocompatibility, and negligible macrophage uptake.  Effective tumor 
accumulation (5% of injected dose) was observed after tail vein injection, which is 
significantly higher than pegylated polymeric spherical nanoparticles of the similar size 
(2.5%) (97).  
Small molecules, such as lidocaine (98), flurbiprofen (98), paclitaxel (99), pirarubicin 
(66), and ellipticine (100, 101), can be loaded into the hydrogels of self-assembling 
peptides.  Liu et al mixed RADA16-I peptide with paclitaxel in water and found 
RADA16-I peptides were able to solubilize and stabilized paclitaxel particles (99).  It was 
proposed that amphiphilic RADA16-I β-sheets coated paclitaxel particles by hydrophobic 
interactions.  The incorporation of paclitaxel particles did not compromise the gelation of 
RADA16-I, although the fraction of β-strand decreased.  A higher peptide concentration 
led to longer release time.  Maximal in vitro anti-tumor effect was achieved when 
paclitaxel was incorporated into 1% (w/v) RADA16-I hydrogels. EAR8-II (AEAEARAR) 
was synthesized to deliver pirarubicin.  At a peptide to drug ratio of 5:1, stable uniform 
nanostructures with a diameter of 700 nm were obtained (66).  
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Hemostasis 
Because of their rapid stimuli-responsiveness, i.e. sol-gel transition, self-assembling 
peptides have been investigated in hemostasis models (102).  Wang et al measured the 
time for hemostasis in a rat spinal cord transection model using RADA16-I (103).  Un-
sonicated 50 µL 1% w/v RADA16-I solution was able to cease the bleeding in 20 
seconds.  Sonication treated RADA16-I took longer time as the reassembly was not 
complete until 24 h later.  Luo et al reported similar efficacy when D-form EAK16-I was 
used in a rabbit liver wound model (104).  The D-form EAK16-I (200 µL 1% w/v 
solution) was able to achieve hemostasis in 20 seconds.  Ions, such as K+, Na+, Ca2+, and 
Mg2+ in the blood trigger the self-assembly and the resultant fibrillar network functions 
as a “fishing-net” in agglutination (104). 
 
Pathogenesis of β-amyloids  
Neurodegenerative conditions, such as Alzheimer’s disease and Parkinson’s disease, are 
associated with the deposition of abnormal protein aggregates, i.e. β-amyloids (105).  β-
amyloids are well-organized β-sheets rich fibrillar structures (76), which are converted 
from native proteins under pathological conditions.  The pathogenesis of β-amyloids has 
been extensively studied using model proteins and peptides (106-108).  The self-
assembly of ionic complementary peptides may provide insight into amyloid formation 
and how to prevent such conversion.  Altman et al studied the plasticity and dynamics of 
a serial of EAK peptides (109). EAK12-d (AEAEAEAEAKAK, truncated from EAK16-
IV) exhibited pH and temperature dependent conformation transitions (β-strand to α-helix 
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at elevated temperature and basic pH).  However, α-helix would eventually convert back 
to β-strand, indicating β-strand represents a lower energy state stabilized by extensive H-
bonding, hydrophobic interactions, and electrostatic interactions (109).  An intermediate 
state may exist during the α-helix to β-strand reconversion as evidenced by lack of an 
isodichromic point.  Existing β-sheets may guide the conversion of α-helix, and resultant 
β-strand will be captured and stabilized by the β-sheets template present.  A similar 
process may exist in β-amyloid formation.  The authors further proposed that increasing 
the activation energy needed for α-helix to β-strand conversion could prevent amyloid 
formation.  This can be achieved through molecular inhibitors that stabilize α-helix or 
sequester the intermediate states. 
 
Summary 
Great advances have been achieved in understanding, designing, and utilizing ionic 
complementary β-sheets based self-assembling peptides.  Owing to their biocompatibility 
and stimuli-responsiveness, these self-assembling peptides represent a major class of 
biomaterials in tissue engineering and drug delivery.  However, no definitive model of 
self-assembly has been reported.  Self-assembly may differ from peptide to peptide.  The 
relationship between molecular peptide structure and final peptide assembly requires 
more scrutinization.  High resolution techniques, such as solid state NMR and x-ray 
crystallography, may be required to fully explore the hierarchy of peptide assembly.  
Experimental evidence is required to support the hypothesis that a functionalized peptide 
(e.g. ALK, DGR, and PGR (34)) can co-assemble with the parent peptide to display 
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bioactive motifs. Despite these challenges, engineering of ionic complementary self-
assembling peptides has tremendous potential in medical and pharmaceutical progresses. 
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CHAPTER 3  
Retaining Antibodies in Tumors with a Self-assembling Injectable 
System 
Abstract 
The performance of an in situ-forming injectable membrane designed to retain antibody 
molecules in vivo is described.  The system entails an aqueous mixture of peptide 
amphiphiles (referred to as “EAK16-II” and “EAKIIH6”) and intermediate proteins (anti-
His-tag antibody and protein A/G) through which therapeutic IgG molecules are co-
localized and oriented.  Scanning electron micrographs show IgG molecules localized on 
the EAK16-II/EAKIIH6 membrane.  IgG were captured via specific interactions and 
remained biologically active in vitro.  Upon administration into mice subcutaneously, the 
amphiphilic peptides co-assembled into stable His-tags displaying materials locally.  The 
system was shown to retain in vivo a fluorescent dye-labeled IgG in two epithelial tumor 
lines.  IgG co-administered with the system were found to remain in 4T1 mouse 
mammary tumors for up to 120 h, while free antibody was cleared within the first 24 h.  
Decreased clearance was also found in B16 melanoma established in mouse footpads.  
These studies demonstrated that the immobilizing mechanism was effective in enhancing 
the retention of IgG locally in vivo.  The injectable system may be used to enhance the 
delivery of immune modulatory antibodies in tumors.  
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Introduction 
Primary tumors can be exploited for the purpose of generating immunity that eliminates 
metastasized cancer cells systemically (21).  Endogenous proteins released from 
apoptotic or necrotic cancer cells are sources of tumor-associated antigens (TAAs).  
Immunological presentation of TAAs by antigen-presenting cells (APCs) activates 
tumor-specific lymphocytes in draining lymph nodes (110, 111).  T and B lymphocytes 
activated and expanded therein eventually migrate to populate all lymphoid organs.  
Whether the responses result in eliminating or promoting the cancer systemically is 
largely dependent upon the immune milieu within which APCs are immersed (112).  
Most common human (and rodent) cancers impose suppressive regimes by which host 
lymphocytes become tolerant of the cancer (2).  Consequently, attempts have been made 
to steer APCs to orchestrate lymphocytes to oppose the cancer by modulating the tumor 
immune milieu.  Examples of this strategy include administration of interleukin and toll-
like receptor agonists into cancer lesions (113-119).  Monoclonal antibodies are an 
important class of immune modulators, but studies have shown that these 
macromolecules are cleared rapidly in tumors (119). 
    The tumor microenvironment poses barriers to the distribution and retention of IgG 
molecules.  Poor distribution is attributed to the high interstitial fluid pressure found in 
many tumors (119).  Pressure gradients originating from the necrotic center force fluids 
toward the periphery of the lesion.  The dense extracellular matrix in many epithelial 
tumors also impedes the distribution of IgG (120).  Excess collagens produced by stromal 
fibroblasts slow diffusion and convection of IgG molecules.  The poor tumor 
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accumulation of intravenously infused IgG inspired the use of intratumoral injection as an 
alternative.  It was thought that the pressure exerted by infusion syringes in tumor could 
overcome the resistance, but macrophages and dendritic cells residing in tumors 
efficiently remove IgG molecules via membrane-bound Fc receptors (121).      
    We sought to develop an injectable platform by which retention of IgG molecules in 
tumors can be enhanced.  We have designed an antibody display system by which IgG 
molecules are localized and oriented on a co-assembly of EAK16-II and EAKIIH6, an 
analogue of the former with six histidine residues (His-tag) appended at the C terminus 
(50).  The working model is that EAK16-II and EAKIIH6 assemble into -sheet bilayers 
that laminate into fibrils with accessible His-tags.  Molecular modeling suggests that the 
amphiphilic repeats in EAK16-II and EAKIIH6 align in an anti-parallel -sheets from 
which the histidines rise above.   In vitro, this His-tag displaying membrane remains 
stable for at least 3 weeks at 37 C (50).  The design exploits the specific interactions 
between protein A/G (pAG) and the Fc region in IgG to orient Fab from the surface 
(Figure 3-1).  The functional utility of the platform has been validated in experiments in 
which membranes loaded with anti-CD4 antibodies immobilize CD4+ T cells from 
splenic lymphocytes in vitro (50).  However, the interactions among each component 
have not been examined. The in vivo assembly and stability of the system has not been 
demonstrated. The current chapter presents evidence demonstrating the assembly and 
stability of the system in living tumors in which near infrared (NIR) dye-conjugated IgG 
were tracked optically in live animals. 
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Figure 3-1 Schematic depiction of the IgG displaying system.  Molecular models of 
IgG were generated from the x-ray structure of an IgG2a antibody (PDB entry 1IGT (53)) 
using Jmol. 
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Materials and Methods 
Materials 
The peptides EAK16-II and EAKIIH6 were custom synthesized by American Peptide 
Company (Sunnyvale, CA) at greater than 90% purity.  Peptides were acetylated and 
amidated at the N and C termini, respectively.  Peptides were reconstituted in sterile 
deionized water (18.2 M at 25C) at 5 mg/mL for EAK16-II and 7.5 mg/mL for 
EAKIIH6.  Rabbit anti-His-tag polyclonal antibody (αH6-IgG, 0.2 mg/mL) was obtained 
from AnaSpec, Inc (San Jose, CA).  Recombinant protein A/G (pAG) was obtained from 
Pierce Biotechnology (Rockford, IL) and reconstituted to 0.25 mg/mL in sterile deionized 
water.  DyLightTM 800 conjugated goat anti-rabbit IgG (Rabbit-IgG800, 1 mg/mL) was 
also purchased from Pierce Biotechnology. DyLightTM 800 conjugated goat anti-chicken 
IgG (Chicken-IgG800) was obtained from KPL (Gaithersburg, MD) and reconstituted to 
1 mg/mL in sterile deionized water.  Transforming growth factor β (TGF-β) IgG1 
antibody (clone 1D11, αTGF-β IgG, 0.2 mg/ml) were harvested from the culture medium 
of 1D11 hybridoma (ATCC, Manassas, VA) and purified using the Montage® antibody 
purification kit with PROSEP®-A media (Millipore, Billerica, MA).  Congo red stock 
solution (0.1%) was purchased from Fisher Scientific (Rochester, NY).  4T1 and B16-
F10 cell lines were obtained from ATCC.  RPMI-1640 and fetal bovine serum (FBS) 
were obtained from HyClone (Logan, Utah).  Penicillin and streptomycin solutions were 
purchased from Lonza (Walkersville, MD).  Trypsin/EDTA was obtained from 
Mediatech (Manassas, VA).   
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Sample preparations 
Samples were prepared as follows unless indicated otherwise.  The system is prepared by 
adding a mixture of αH6-IgG (0.3 µM), pAG (0.15 µM), and a second IgG (0.3 µM) into 
the peptide mixture of EAK16-II (1.3 mM) and EAKIIH6 (0.325 mM).  This premixed 
system self-assembles after being added into PBS in vitro or injected into mice in vivo. 
Control groups were prepared without one or more components with the remaining 
materials maintained at the same concentrations by substituting with sterile deionized 
water.    
 
Optical and scanning electronic microscopy 
Bright field imaging was conducted as follow.  Five microliters of each sample was 
added into 5 µL of a diluted Congo red solution (0.01% in PBS) spotted on a glass slide 
(Fisher Scientific, Waltham, MA).  Images were captured immediately using a Vista 
VisionTM inverted microscope (VWR, Radnor, PA) equipped with a ProgRes C3 cooled 
CCD camera (Jenoptik AG, Jena, Germany).  To prepare samples for scanning electron 
microscopy (SEM), membranes were formed in PBS on a polyethylene terepthlate (PET) 
membrane (8 m pore size), fixed in 10% formalin, and rinsed with deionized water three 
times and lyophilized.  Samples were mounted on double-sided carbon tape affixed to an 
aluminum specimen holder.  Images were captured using a Hitachi S-3400N microscope 
at a working distance between 5-7 mm with a 5.0 kV accelerating voltage under vacuum 
(<1 Pa).  Particles appearing in images were evaluated using the software Axiovision 
4.6.3.  By selecting particles in the image field, the bound height and width of each 
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particle were determined and these two values were averaged to generate the calculated 
individual particle size.  Measurements consisted of selecting all discrete particles from 
three different areas.  Particles from different areas have comparable average sizes (15.0 
nm, 17.0 nm, and 17.6 nm) and are pooled together for further analysis, resulting in a 
total of 421 particles analyzed.   Distances between two adjacent particles (on the same 
fibril or different fibrils) were measured using the same software.   
 
Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) 
In vitro prepared membranes were incubated in PBS at 37 ℃  for 24 hr and the 
supernatants were analyzed using the denaturing NuPAGETM Novex® 4-12% gels (Life 
Technologies, Carlsbad, CA).  Proteins were visualized using the SilverQuestTM staining 
kit (Life Technologies) with a reported detection limit of 0.3 ng and imaged using the 
Kodak 440 Image Station (Rochester, NY).  Band intensities were quantified using 
ImageJ (version 1.45s).  
 
Antigen binding activity of immobilized antibodies 
The function of IgG associated with the membrane was determined using ELISA to 
measure TGF-β as a model antigen.  Membranes were formed in PBS on PET 
membranes or in solution. 0.5 mL of TGF-β standard solution or culture media of B16-
F10 and 4T1 cells were applied to the system.  Samples were either rinsed with distilled 
water (3X) or centrifuged (16,000 g for 5 minutes at room temperature).  Concentrations 
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of TGF-β in filtrate or in supernatant were determined using the DuoSet® mouse TGF-β 
kit (R&D system, Minneapolis, MN).  Absorbance at 450 nm and 570 nm were measured 
using a Perkin Elmer VICTOR 1420 reader (Perkin Elmer, Waltham, MA). 
 
Mice, tumor inoculation, and imaging  
Six to eight week old female (certified-virus-free) BALB/c and C57BL/6 mice were 
purchased from Charles River Laboratories (Wilmington, MA) and housed in the 
Duquesne University Animal Care Facility.   Animals were handled in accordance to 
protocols approved by the Duquesne University Institutional Animal Care & Use 
Committee.  BALB/c and C57BL/6 mice were inoculated with 4T1 or B16 tumor cells, 
respectively.  Cell lines were cultured in RPMI-1640 (4T1) or DMEM (B16) medium, 
supplemented with 10% FBS and antibiotics.  Tumor cells in the exponential growth 
phase (between passages 5 to 14) were harvested and suspended in sterile saline.  5×105 
cells suspended (in 100 µL sterile saline) were inoculated subcutaneously in BALB/c 
mouse flank (4T1) or C57BL/6 mouse footpad (B16-F10).  Only tumors of equivalent 
size (perpendicular diameters) were used in the studies: 0.5 × 0.5 cm for flank tumors and 
0.2 × 0.2 cm for footpad imaging experiments.  Recognizing that the melanin in B16 
melanocytes may impede photon excitation and emission, the fluorescent intensities 
obtained in this model were not directly compared to those obtained in 4T1 tumors. 
    Footpads were collected and stretched out on a 15 × 100 mm dish using scotch tape for 
ex vivo imaging.  Images were captured using an Odyssey Imager (Li-Cor, Inc., Lincoln, 
NE) and measured at an intensity of 1.0 with focal distances of 3.2 mm and 3.5 mm.  
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Fluorescence quantification was performed by drawing a polygon outlining the shape of 
the footpad.  The averaged signal of three blank footpads at each focal distance was 
subtracted as background.  Data reported represent fluorescence intensities averaged from 
the measurement performed at each focal distance. 
    Anesthetization was induced using isoflurane (induction 5%, maintenance 3 %) for real 
time in vivo imaging.  Abdominal hairs were removed prior to scanning.  Mice were 
scanned prior to injection and monitored at the indicated times after injection using a 
Pearl Impulse imager (Li-Cor, Inc.). All images were collected using the same threshold 
and resolution (170 µm) settings.  Oval-shaped regions of interest were defined at the site 
of injection and the contralateral flank as background.  Fluorescence intensity was 
quantified using the Impulse (2.0) software (Li-Cor, Inc.) with a standard deviation 
multiplier of 10 and a search limit of 100 pixels.  
 
Tracking retention in vivo  
In vivo assembly and stability of EAK16-II/EAKIIH6 composite was tracked using the 
NIR dye (=800 nm)-labeled goat anti-rabbit antibody (Rabbit-IgG800, 0.03 µM), which 
binds to the rabbit derived H6-IgG. EAK16-II, EAKIIH6, αH6-IgG, and Rabbit-IgG800 
were mixed and injected subcutaneously at the posterior flank or footpads of BALB/c 
mice. Signal at the posterior flank was recorded real time using a Li-Cor Pearl Impulse 
Imager for up to 11 days. Fluorescence intensity in the footpad was imaged using a Li-
Cor Odyssey Imager ex vivo at 30 min, 6, 24, 48, and 72 h.  Stability of IgG display 
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system in tumors was tracked using the NIR dye (=800 nm)-labeled goat anti-chicken 
antibody (Chicken-IgG800, 0.03 µM). The system was injected into 4T1 tumor on 
BALB/C mice or B16 tumor on C57BL/6 mice.  Signal in 4T1 tumor was monitored real 
time on Pearl Impulse imager over 4 days.  Fluorescence intensity in B16 tumor in the 
footpad or tumor section (5 m thickness) was imaged on Odyssey ex vivo 24 h or 5 min 
after injection respectively.   
    αRabbit-IgG800 was used to study the assembling and kinetic stability of EAK16-
II/EAKIIH6/αH6-IgG.  The αH6-IgG is rabbit derived and it is not fluorescently labeled 
(no near infrared dye labeled format is available commercially).  Therefore, a secondary 
IgG is used to detect binding of the primary antibody. αRabbit-IgG800, which is derived 
from goat (against rabbit), can bind to the rabbit derived αH6-IgG.  αChicken-IgG800 was 
used as a model therapeutic IgG to demonstrate the assembling and stability of the full 
system in tumor. αChicken-IgG800, which is derived from goat (against chicken), does not 
bind to the rabbit derived αH6-IgG.  Consequently, it can only be displayed onto the 
membrane by interacting with pAG with its Fc domain. 
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism 5.0.  Data were analyzed using one 
way ANOVA and the Tukey-Kramer multiple comparison (α=0.05) or one-tailed 
Student’s t-test (α=0.05) as indicated.  Data shown represent mean and standard deviation.  
n indicates number of replicates/animals in each group.  
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Results 
The co-assembly of EAK16-II and EAKIIH6 was designed to display model therapeutic 
antibodies via intermediate proteins (Figure 3-1).  Anti-His-tag antibodies (H6-IgG) 
cross-link His-tags in the EAK16-II/EAKIIH6 membrane and, at the same time, provide 
Fc for recognition by pAG.  The hexavalent pAG allows a second (i.e. therapeutic) 
antibody to be displayed via Fc, thereby orienting the Fab domains away from the 
membrane surface.  To confirm this design, the amphiphilic peptides (EAK16-II and 
EAKIIH6) and intermediate proteins (H6-IgG and pAG) were characterized with or 
without an IgG (clone 1D11, (122)) that binds to transforming-growth factors (TGF- as 
a model therapeutic antibody.  Staining with Congo red revealed the classical orange -
fibrils in EAK16-II (Figure 3-2a) and EAK16-II/EAKIIH6 (Figure 3-2b) membranes.  As 
previously reported by Zheng et al (50), these membranes were not seen in buffers 
containing EAKIIH6 without EAK16-II (Figure 3-2c).  Successive additions of H6-IgG 
(Figure 3-2d), pAG (Figure 3-2e), and αTGF-β IgG (Figure 3-2f) resulted in retracted and 
denser morphologies.  These morphological changes may suggest the two antigen binding 
domains of H6-IgG could effectively crosslink EAK16-II/EAKIIH6 fibrils when they 
bind to His-tags on two different fibrils.  Since optical microscopy has limited 
magnification, it was used to demonstrate that macroscopic and Congo red stainable 
membranes had formed.  Details of the antibody display system were further investigated 
under SEM.  
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Figure 3-2 Optical micrographs of samples.  Samples contain (a) EAK16-II, (b) 
EAK16-II/EAKIIH6, (c) EAKIIH6, (d) EAK16-II/EAKIIH6 + H6-IgG, (e) EAK16-
II/EAKIIH6/H6-IgG/pAG, and (f) EAK16-II/EAKIIH6/H6-IgG/pAG/αTGF-β 1 IgG.  
Images (40X; scale bar-50 µm) were captured using a cooled CCD camera immediately 
after solutions (5 L) containing the respective peptides and/or proteins were spotted 
onto glass slides into an equal volume of PBS (Congo red 0.01%).  Figure adapted from 
reference (123) with permission. Copyright (2013) American Chemical Society. 
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SDS-PAGE 
In SDS-PAGE, proteins are separated based on their molecular weights with smaller 
proteins migrated farther in a polyacrylamide gel.  SDS-PAGE was used to characterize 
the non-covalent associations in the system by analyzing the fraction remained in solution 
(Figure 3-3a).  Greater than 90% of αTGF-β IgG (~160 kDa) were captured by the 
membrane (Figure 3-3b, lane II).  Without EAKIIH6, less than 25% of αTGF-β IgG 
loaded were associated with the insoluble membrane (Figure 3-3b, lane III).  Without 
H6-IgG (~110 kDa), 31% of αTGF-β IgG were found in the soluble fraction (Figure 3-
3b, lane IV), possibly due to non-specific entrapment of complexes formed between 
αTGF-β antibodies and pAG (~60 kDa, not visible in image).  Larger complexes of 
αTGF-β antibodies and pAG are more susceptible to be trapped within the EAK16-
II/EAKIIH6 fibrous network.  Without pAG, capture of αTGF-β IgG was low (< 25%) 
(Figure 3-3b, lane V).  The band near the 3.4 kDa mark is attributed to excess EAKIIH6 
that is excluded from assembly, which indicates that prototype formulation used requires 
further optimization in the future.  The amount of EAK16-II needed to completely 
incorporate certain amount of EAKIIH6 was further studied in chapter 5.  These results 
indicate that the intermediate proteins H6-IgG and pAG mediated the capture of αTGF-
β IgG by the co-assembly.     
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Figure 3-3 Analysis of interactions in the membrane system using SDS-PAGE 
electrophoresis.   (a) Unincorporated fraction from membranes settled under gravity in 
500 µl PBS incubated at 37C overnight. (b) Lane I: αTGF-β IgG; lane II, EAK16-
II/EAKIIH6/H6-IgG/pAG/αTGF-β IgG; lane III, EAK16-II/H6-IgG/pAG/αTGF-β 
IgG (system without EAKIIH6); lane IV, EAK16-II/EAKIIH6/pAG/αTGF-β IgG (system 
without H6-IgG); lane V, EAK16-II/EAKIIH6/H6-IgG/αTGF-β (system without 
pAG).  (c) Band intensities were quantified using ImageJ.  Percent loading was 
determined based on the amount of αTGF-β IgG added to the system (lane I).  Figure 
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adapted from reference (123) with permission. Copyright (2013) American Chemical 
Society. 
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Scanning electron microscopy  
Having established that a model therapeutic IgG could be displayed on the membrane via 
His-tags, SEM was used to examine the structures in detail (Figure 3-4).  Micrographs 
with successive additions of each component were compared.  Consistent with those 
reported by other groups (58, 124), the mean width of the fibrils in the EAK16-II network 
(Figure 3-4a) was determined to be 9.3 nm (2.1).  The EAK16-II/EAKIIH6 co-assembly 
was found to have a similar morphology seen in pure EAK16-II but with thicker fibrils 
(mean width = 15.9 nm2.6) (Figure 3-4b), which may result from appending His-tags.  
Successive additions of H6-IgG (Figure 3-4c), pAG (Figure 3-4d) and αTGF-β IgG 
(Figure 3-4e) coincided with the appearance of particulates clustering at an average of 
17.4 nm (7.3) apart when all components were added.  The particulates were found to 
have a mean diameter of 16.6 nm (±10.6), a dimension consistent with the length of two 
extended Fab domains (16.9 nm) as suggested by Ma et al (33).  Since distances among 
adjacent particles both on the same fibril and different fibrils were measured, particles 
closer than domains (16.9 nm) may locate on two different fibrils.  The size range (Figure 
3-4f) suggests individual (non-aggregating) αTGF-β IgG molecules were the most 
frequent species.  The smaller particulates (5-16 nm) might represent individual pAG on 
the fibrils.  Larger particulates (16-38 nm) might be attributed to IgG/pAG imaged from 
multiple perspectives (relative to the vertical axis of the complex) due to convolutions in 
the entangled fibrils.  The few particulates greater than 38 nm might represent each pAG 
bound with two or more IgG molecules (Figure 3-4g).  These micrographs confirmed that 
IgG molecules were spatially clustered on the membrane. 
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Figure 3-4 SEM images of samples.  SEM images (5000X magnification) of samples 
with (a) EAK16-II,  (b) EAK16-II/EAKIIH6, (c) EAK16-II/EAKIIH6 cross-linked with 
H6-IgG, (d) EAK16-II/EAKIIH6/H6-IgG/pAG, and (e) EAK16-II/EAKIIH6/H6-
IgG/pAG/αTGF-β IgG.  Samples were fixed and lyophilized prior to evaluation.  (f) Size 
distribution of the particles in image e was evaluated using an interactive measurement 
program in Axiovision 4.6.3.  (g) Proposed configurations of IgG complexes on fibrils.  
Figure adapted from reference (123) with permission. Copyright (2013) American 
Chemical Society.  
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Antigen binding activity of immobilized antibodies 
To demonstrate that the immobilized antibodies remained active, αTGF-β IgG loaded 
membranes were tested in vitro using ELISA (Figure 3-5).  Membranes established with 
αTGF-β or an irrelevant IgG were placed on a mesh filter (pore size =8 m) onto which 
media containing TGF-were placed.  The assumption is that displayed antibodies would 
be able to recognize and bind to targeted antigens because their native conformations and 
activities would not be disrupted by the tethering mechanisms.  Therefore, a lower 
concentration of TGF- shall be expected in the filtrate.  Concentrations of TGF- in the 
filtrate (unbound) were measured using ELISA.  The system removed 57% to 61% of 
TGF-β from the B16 and 4T1 media, respectively (Figure 3-5b).  This was calculated by 
comparing the concentrations of cytokine in the flow-through with (“αTGF-β IgG”) and 
without (“Inert membrane only”) the system.  Loading an irrelevant antibody (“Irrelevant 
IgG”) onto the membrane resulted in no depletion.  The membrane depleted 94 pg (3.8 
fmol) of TGF- per microgram (6.7 pmol) of αTGF-β IgG in the system (Figure 3-5b).  
Similar results were observed when the components were admixed into TGF-β containing 
media.  Using this second method, it was determined the system removed 71% to 82% of 
TGF-β from the B16 and 4T1 media, respectively (Figure 3-5c).  141 pg (5.6 fmol) of 
TGF- were depleted per microgram (6.7 pmol) of αTGF-β IgG (Figure 3-5c).  This 
relatively low efficiency was not unexpected.  The cytokine concentrations are below the 
saturation point at which all theoretical available antigen-binding sites would be occupied.  
The loading capacity of antibodies and available antigen binding sites warrants further 
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studies.  These data show that IgG molecules localized on the membrane remained in its 
native conformation and were able to bind to its cognate antigen. 
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Figure 3-5 Antigen binding function of immobilized αTGF-β IgG.  (a) Self-
assembling components, including αTGF-β IgG, were formed on mesh filter or in PBS 
and analyzed for antigen neutralizing capacity.  Concentrations of TGF-β in the filtrate (b) 
or supernatant (c) were determined using ELISA.  Statistical significance was confirmed 
by one way ANOVA and Tukey’s multiple comparisons (n=3, ***p<0.0001, **p<0.01).  
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Concentrations of TGF- in media were below saturation and not all αTGF-β IgG 
antigen-binding sites were expected to be occupied.  Figure adapted from reference (123) 
with permission. Copyright (2013) American Chemical Society. 
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In vivo assembly and stability of EAK16-II/EAKIIH6 membrane co-assembly 
The in vitro evidence shows that the EAK16-II/EAKIIH6 membrane provided a physical 
mechanism by which IgG molecules can be co-localized.  To demonstrate that the His-tag 
surface could self-assemble in vivo, the peptides were injected (in deionized water) 
subcutaneously into the posterior flank of BALB/c mice.  In addition to the amphiphiles, 
H6-IgG were co-administered to cross-link the His-tags in situ.  Assembly of the three 
components, namely, EAK16-II, EAKIIH6 and H6-IgG, was monitored using a NIR 
dye (=800 nm)-labeled goat anti-rabbit antibody (Rabbit-IgG800).  This dye-labeled 
antibody binds to H6-IgG.  Figure 3-6a shows that the composite (“His-tagged 
membrane”) remained at the injection site for up to 264 h, as evidenced by the 
concentrated fluorescence at the site of injection.  Without EAKIIH6, the fluorescent 
intensity (FI) at the injection site was significantly less;  at 24 h, mice received EAK16-
II/EAKIIH6/H6-IgG registered a FI of 646 (arbitrary unit), compared to 118 in mice 
that received EAK16-II/H6-IgG.  Mice received only Rabbit-IgG800 showed relatively 
low local fluorescence (61) at 24 h and fell near background thereafter (Figure 3-6b).  
These results show that the co-assembly of EAK16-II/EAKIIH6 displayed His-tags in 
living mice.   
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Figure 3-6 Stability of EAK16-II/EAKIIH6 (molar ratio 4:1) co-assembly in BALB/c 
mouse subcutaneous flank.   Solutions containing EAK16-II, EAKIIH6, H6-IgG, and 
Rabbit-IgG800 (“His-tagged membrane”) were injected into mice (n=2) using insulin 
syringes.  “Membrane” refers to animals received EAK16-II, H6-IgG, and Rabbit-
IgG800.  “Rabbit-IgG800” indicates animals injected with only the fluorescent antibody.  
(a) Representative real time images of fluorescent signal in the same mouse.  All images 
were exported with same setting from Licor Pearl Impulse. (b) Kinetic profiles of 
fluorescent intensity decay.  Fluorescent quantifications obtained from mice received 
membranes without H6 and those received free Rabbit-IgG800 were modeled as a 
monophasic decay using GraphPad Prism.  (c) Schematic of the mode of His-tag 
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detection.  Figure adapted from reference (123) with permission. Copyright (2013) 
American Chemical Society. 
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    Mice injected with EAKIIH6 and H6-IgG showed near background fluorescence 
after 24 h (Figure 3-7).  This result confirmed in vivo that without EAK16-II, EAKIIH6 
cannot assemble into insoluble membrane in subcutaneous space in mice.  Consequently, 
without EAK16-II, EAKIIH6 could not slow down the clearance of IgG in tumors.  This 
is consistent with data previously shown.  The micrograph Figure 3-2c in the current 
chapter indicates the lack of macroscopic membranes when EAKIIH6 was spotted in 
buffers on glass slides.  Additional supporting evidence has been described in Zheng’s 
dissertation work (50, 52). Without EAK16-II, EAKIIH6 adopts mostly -helical and not 
-strand conformation required for self-assembly; EAKIIH6 per se does not co-
precipitate nickel-bound horseradish peroxidase from aqueous buffers.   
 
Figure 3-7 Representative time-lapse images showing the lack of gelation with 
EAKIIH6 in vivo.  Plotted data show fluorescent decay of Rabbit-IgG800 co-injected 
with H6-IgG and EAKIIH6 in a BALB/c mouse (n=1).  The amount of EAKIIH6 
(187.5 g) injected was equivalent to the total peptide weight in the EAK16-II/EAKIIH6 
(molar 4:1) mixture. All images were exported with the same settings from Licor Pearl 
Impulse.  Figure adapted from reference (123) with permission. Copyright (2013) 
American Chemical Society. 
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    Comparing the rates of FI decline revealed that cross-linking of the His-tags was 
critical in maintaining antibodies locally (Figure 3-6b).  From 30 min to 24 h, the rate of 
decline in mice that received EAK16-II/EAKIIH6/H6-IgG was determined to be 0.48% 
of the initial fluorescence (InitF; 30 min after injection) per hour, which is an order of 
magnitude slower than those in mice that received EAK16-II/H6-IgG (3.2%InitF.h-1).  
Free Rabbit-IgG800 also declined rapidly at 4.0%InitF.h-1.  Thereafter, the His-tag cross-
linked membrane remained relatively stable; from 24 h to 264 h, FI in mice that received 
EAK16-II/EAKIIH6/H6-IgG declined at a relatively slow rate of 0.19%InitF.h-1 (Figure 
3-6b).   The decline of free Rabbit-IgG800 followed first-order kinetics (R2=0.98, Ke = 
0.12 h-1), as in the case when the same fluorescent antibody was co-administered with 
EAK16-II and H6-IgG (R2=0.94, ke = 0.06 h-1).  Clearance of Rabbit-IgG800 in mice 
injected with His-tagged membrane indicated multi-compartmental kinetics, but it was 
clear that the AUC (1.4×105 FI.h) was 10-fold and 11-fold higher than the membrane 
without His-tags (1.3×104 FI.h) and free fluorescent IgG (1.2×104 FI.h), respectively.         
    Similar observations were made in mouse footpads.  Injection of Rabbit-IgG800 alone 
resulted in near complete loss of fluorescence within the first 24 h (Figure 3-8a).  When 
injected with EAK16-II, EAKIIH6 and H6-IgG, Rabbit-IgG800 remained at injection 
site longer compared to when the same antibody was injected with only EAK16-II and 
H6-IgG.  Local FI was found to be 57.5 (8.0) and 15.4 (1.6) (p= 0.0061), respectively, 
48 h after injection.  From 30 min to 24 h, the rate of FI decline in mice that received 
EAK16-II/EAKIIH6/H6-IgG was determined to be 2.3%InitF.h-1, which was slower 
than those in mice that received EAK16-II/H6-IgG (3.4%InitF.h-1) and Rabbit-IgG800 
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(4.0%InitF.h-1).  Between 24 h to 72 h, FI in mice that received EAK16-
II/EAKIIH6/H6-IgG declined at a relatively slow rate of 1.1%InitF.h-1.  Marginal 
fluorescence was seen in mice that received EAK16-II/H6-IgG in the same period 
(Figure 3-8b).  These observations in two anatomical sites (flank and footpad) established 
that the self-assembling process could take place in vivo and that His-tag cross-linked 
EAK16-II/EAKIIH6 remained locally for an extended duration.   
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Figure 3-8 Stability of EAK16-II/EAKIIH6 in BALB/c mouse footpads.  (a) 
Representative ex vivo images of footpads injected with solutions containing EAK16-II, 
EAKIIH6, H6-IgG, and Rabbit-IgG800 (“His-tagged membrane”) using insulin 
syringes.  “Membrane” refers to animals received EAK16-II, H6-IgG, and Rabbit-
IgG800.   “Rabbit-IgG800” indicates animals injected with only the fluorescent antibody.  
All images were exported with the same settings from Licor Odyssey. (b) Fluorescent 
intensities was analyzed by one way ANOVA and Tukey’s multiple comparisons (n=3; 
***p<0.0001, **p<0.01, *p<0.05).  Figure adapted from reference (123) with 
permission. Copyright (2013) American Chemical Society. 
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Stability of IgG displaying system in tumors 
Having demonstrated the stability of the His-tag membrane in vivo, we next investigated 
the ability of intermediate proteins to retain IgG with the membrane in tumors.  This was 
examined using two mouse tumor cell lines.   The mammary line 4T1 arose from a 
spontaneous malignant lesion in a BALB/c mouse (125) and the B16-F10 line was 
derived from a melanoma in a C57BL/6 mouse (126).  While both B16-F10 and 4T1 are 
of epithelial origins, they differ in their physical properties.  The extracellular matrix of 
4T1 tumors is relatively dense, while B16-F10 tumors tend to contain more fluid.  
McGuire et al reported that the collagen content in 4T1 tumors is approximately six times 
of that in B16-F10 tumors (124).  Consequently, 4T1 tumors are less deformable 
compared to B16-F10 tumors.  The difference might affect the efficiency of the 
assembling process and retention.  Tumors are palpable about 10 days after inoculation 
and ready for experiments when they reach about 0.5 cm × 0.5 cm, at which angiogenesis 
and inflammation are adequately developed (127-129).  However, the anatomical 
difference also dictated the stage at which the tumors were used in the experiments.  
Limited space is available for B16 tumors to grow in the mouse footpad, while 4T1 
tumors established in the posterior flank can expand considerably.  Hence, B16 and 4T1 
tumors were studied at sizes of 0.2 cm × 0.2 cm and 0.5 cm × 0.5 cm respectively. 
    Retention of antibodies in 4T1 tumors was monitored in live mice using the Li-Cor 
Pearl Imager.  Chicken-IgG800 injected without the assembling components retained 
poorly in 4T1 tumors (Figure 3-9a); after 24 h, local FI decreased from 249 to near 
background level at a rate of 10% InitF.h-1.  Likewise, Chicken-IgG800 injected with 
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only pAG did not accumulate beyond 24 h.  Conversely, Chicken-IgG800 co-
administered with the assembling components remained in tumors for at least 120 h.  
Between 24 to 120 h, retention of the fluorescent antibody appeared steady, as evidenced 
by the slow rate of fluorescence decline during the period (Figure 3-9b).   
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Figure 3-9 Live animal imaging of membrane-immobilized IgG in 4T1 tumors.   
Solution mixture of EAK16-II, EAKIIH6, H6-IgG, pAG, and Chicken-IgG800 
(“System”) were injected into medium size 4T1 tumors established on the posterior flank 
of BALB/c mice.  Controls include injecting all components without pAG (“no pAG”) or 
without the amphiphilic peptides (“Chicken-IgG800 + pAG”).  Fluorescent antibodies 
(“Chicken-IgG800”) in saline were also included as a control.  (a) Representative images 
of fluorescence over time in the same mice in each group.  All images were exported with 
the same settings from Licor Pearl Impulse.  (b) Fluorescent intensity in tumors injected 
with all components (“System”) or Chicken-IgG800 over time (n=2). The time of 
injection was based on the tumor reaching the half-maximal allowable size.  Figure 
adapted from reference (123) with permission. Copyright (2013) American Chemical 
Society. 
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    Similar results were observed in B16-F10 tumors established in the footpads of 
C57BL/6 mice (Figure 3-10a).  Free Chicken-IgG800 was not detectable after 24 h, but 
fluorescence from the antibody administered with the clustering components remained 
locally at least 4-fold higher (Figure 3-10b).  Taken together, these data indicate that the 
clustering system can partially overcome the IgG clearance mechanisms in the tumor 
microenvironment.  To determine the extent of antibody distribution, tumors were 
excised 5 minutes after injection and sectioned (5 m).  Figure 3-10c shows sections of a 
B16 tumor (implanted on the flank) representing the edge of the lesion towards the center 
and out to the opposite edge.  All sections show strong fluorescence.  It could therefore 
postulate that the pressure exerted from the syringe injection drove the peptides and 
proteins through the interstitial gaps in the lesion.  The convective flow takes place 
simultaneously with the self-assembling process.  As the self-assembly completes, 
antibodies are stably displayed to resist the IgG clearance in tumors. 
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Figure 3-10 Ex vivo imaging of membrane-immobilized IgG in B16-F10 tumors.   
The time of injection was based on the size of the tumor reaching the half-way point 
limited by the anatomy.  Solution mixtures of EAK16-II, EAKIIH6, H6-IgG, pAG, and 
Chicken-IgG800 (“System”) were injected into of C57BL/6 mouse footpads with visible 
and palpable tumors.   Fluorescent antibodies (“Chicken-IgG800”) in saline were 
included as the control.  (a) Fluorescence in B16 melanoma 24 h after injection of dye-
labeled IgG.  All images were exported with the same settings from Licor Odyssey.  (b) 
Statistical significance was confirmed by Student’s t test (n=3; **p <0.01). (c) Optical 
outline (top panel) followed by fluorescence images of tissue sections (5 m) of a B16 
tumor (established on the flank of a C57BL/6 mouse) injected with all components 
(“System”) showing permeation of dye-labeled IgG throughout the lesion.  Figure 
adapted from reference (123) with permission. Copyright (2013) American Chemical 
Society. 
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Discussion 
We describe herein an injectable system by which IgG molecules can be retained in vivo 
through directional binding.  Immobilization of antibody molecules onto a common 
surface could be accomplished by adsorption through electrostatic interactions or 
hydrophobic means (130, 131).  Such random associations often result in altered protein 
conformations, leading to denaturation and loss of functions.  Direct coupling of 
antibodies to a chemically activated surface might generate overly crowded proteins, 
resulting in diminished function due to steric hindrance (131).  Fc-binding proteins such 
as pAG have been used as intermediates to orient Fab away from the adsorptive surface 
(132).  The strong affinities of proteins A and G (equilibrium constants ranging from 1.13 
x108 to 2.90 x107 M-1) (133) for Fc ensure stable association and proper orientation.  
While the strategy of employing intermediate proteins to immobilize antibodies has been 
explored in vitro, few studies have demonstrated the extent to which such assembling 
could take place in vivo.              
    In the present chapter, we show that co-assembly of EAK16-II and EAKIIH6 can be 
established in vivo by injection using standard syringes (28’ gauge).  The co-assembly 
displayed His-tags for up to 11 days.  It should be noted that mice administered with the 
peptide amphiphiles behaved normally and exhibited no gross systemic toxicities (food 
intake and body weight) for the duration of the experiment.  The immobilizing system 
could be used to partially overcome the antibody clearance mechanisms in tumors, as 
evidenced by the prolonged retention of IgG in the 4T1 and B16-F10 lesions.  In both 
models, immobilized IgG remained in tumors significantly longer than free IgG.  As 
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suggested in studies reported by others (134, 135), infusions provided the convective 
force to drive the self-assembling components through the tumor interstitium, dragging 
the fluorescent IgG along into the tumor mass.  Because the Fc domains of membrane-
bound IgG were occupied by pAG, clearance by phagocytes via Fc receptors was 
inhibited.    The eventual clearance of the IgG from tumors likely resulted from gradual 
loss of H6-IgG and/or pAG non-covalently associated with the fibrils.  It might also 
result from dissociation of EAKIIH6 from the EAK16-II/EAKIIH6 co-assembly in the 
tumor microenvironment.   
    The SEM images showed particulates clustered on fibrils.  These particulates were 
within a size range consistent with predicted molecular dimensions of IgG (Figure 3-4g), 
which implied that antibodies were displayed on the membrane.  Smaller but sparse 
particulates could be seen in membranes added with only H6-IgG (Fig. 3-4c).  Mixing 
two different peptide amphiphiles yielded fibrils with increased width possibly due to 
appending His-tags.  The length of two extended Fab domains in an IgG molecule has 
been estimated about 16.9 nm.  Each IgG should be at least 17 nm apart along the fibril 
length to avoid steric interference.  On the other hand, optimizing the density of bioactive 
IgG would have to consider the nature of the target.  For soluble proteins, the dimensions 
(in which diameters typically range in the tens of nanometers) of the monomers or 
oligomers would dictate the optimum. For the much larger ( > 10 m) cellular targets, 
concentration of membrane-bound antigens would likely override the spatial arrangement 
of antibodies on the membrane.   
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    SDS-PAGE demonstrated that the association between a model IgG and the EAK16-
II/EAKIIH6 co-assembly was specifically mediated by the intermediate proteins.  
Loading of the model therapeutic IgG (anti-TGF-) was highly efficient, and was a 
function of pAG, H6-IgG and His-tags.  Non-specific interactions might be attributed to 
adsorption of proteins within cavities in the crossed fibrils.  High molecular weight 
complexes of IgG/pAG might be entrapped within the membrane.  IgG displayed on 
EAK16-II/EAKIIH6 was demonstrated to bind to its cognate antigen.  Because the design 
does not involve chemical coupling, antibody molecules are less likely to denature.  The 
in vitro characterization suggests robust coacervation of the components.    
      
Conclusions 
The current chapter provides both in vitro and in vivo proof-of-concept evidences that 
antibodies are displayed onto EAK16-II/EAKIIH6 membrane through intermediate 
proteins (αH6-IgG and pAG). In SDS-PAGE, more than 90% of model IgG added were 
associated with the membrane.  Without any of the components (EAKIIH6, αH6-IgG, or 
pAG), a higher fraction of antibodies remained in the solution.  The small fraction of 
antibodies removed from solution were possibly entrapped within cross-linked fibrils 
non-specifically.  SEM data indicate antibodies were successfully displayed onto the 
membrane.  The sizes of clustered particulates on fibrils corresponded well with the 
distance of two Fab domains, which suggests most His-tags displayed one IgG in current 
formulation.  One major concern with our antibody display system is the antigen binding 
activity of displayed antibodies.  Using TGF-β as the model antigens, displayed anti-
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TGF-β IgG remained biologically active and were able to remove TGF-β from three 
source media.  The assembly and stability was demonstrated in vivo.  EAK16-II and 
EAKIIH6 can self-assemble in vivo to provide accessible His-tags stably for up to 11 
days. Using the described antibody display system (EAK16-II, EAKIIH6, αH6-IgG and 
pAG), antibodies are retained effectively in tumor after intratumoral injection. 
    Nonetheless, SDS-PAGE data shows there was excessive EAKIIH6 in the formulation 
used (molar ratio of EAK16-II: EAKIIH6 = 4:1, Figure 3-3).   After intratumoral 
injection, a majority of antibodies injected were cleared from the site of injection in 24 h 
(Figure 3-9).  Hence, stepwise optimization is required for maximal performance in vivo.  
The antibody loading capacity and available antigen binding sites warrants close 
examinations.  This may be investigated by escalating the amount of antigen added until 
saturation is reached.  The magnification of SEM images was not high enough to reveal 
the orientation and number of antibodies displayed.  Cryo-transmission electron 
microscopy (Cryo-TEM) might provide further details of the antibody display system 
(136, 137).   In addition, the in vivo therapeutic advantages remain to be demonstrated.  
The ability to reduce IgG clearance in tumors opens opportunities for using therapeutic 
antibodies to modulate cancer-associated T cells.  These include anti-CTLA-4 IgG that 
amplifies T cell responses toward cancers.  Intravenous infusion of these agents has been 
associated with immune related toxicities due to non-specific effects on bystander 
leukocytes (138).  An effective local depot could mitigate these complications.   
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CHAPTER 4  
Antibody Functionalized Peptidic Membranes Impede Trafficking of 
Allogeneic Skin Antigen Presenting Cells 
Abstract 
The performance of the in situ antibody display system to attenuate allograft rejection 
was tested in a skin transplant mouse model.  Self-gelling anti-donor antigen presenting 
cells (dAPCs) membrane was shown to attenuate T cell activity in recipient mice to donor 
graft with fully mismatched major histocompatibility complexes (MHC).  Functionalized 
peptidic membranes were used to impede trafficking of dAPCs to draining lymph nodes 
in recipient mice.  Membranes loaded with antibodies were found to remain underneath 
normal and grafted skins for up to 6 days.  dAPCs were targeted by using an antibody 
that binds to a class II MHC molecule (I-Ad) expressed exclusively by donor cells.  In 
treated mice, fewer dAPCs were found in graft-draining lymph nodes.  Recipient T cells 
from these mice produced lower concentrations of interferon-gamma (IFN-) cultured ex 
vivo with donor cells.  Taken together, the data suggest that the strategy has the potential 
to alter the natural course of transplant rejection.  The platform can be fit with different 
antibodies to mitigate multiple rejection mechanisms simultaneously.    
 
Introduction 
In this chapter, performance of the in situ forming fibrillar EAK16-II/EAKIIH6 
membrane to attenuate immune rejection of allogeneic skins is described.  Human skin 
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allograft is the “gold standard” biological dressing for temporary wound closure (139).  
Patients with partial and full-thickness burns benefit from intact epidermis and dermis;  
together these serve as a protective barrier to minimize desiccation of the underlying 
exposed tissues, limit water evaporation, reduce bacterial contamination, relieve pain, and 
promote wound healing by accelerating re-epithelialization (139).  However, the 
heightened antigenicity of skin allografts drives powerful allospecific T cell responses in 
recipients (7).  
    Calcineurin inhibitors (cyclosporine A and tacrolimus) and mAb targeting IL-2 
receptors are the mainstays in managing allograft rejection (140-142).  These agents exert 
their immunosuppressive effects by dampening the activation, proliferation and survival 
of all T cells through down-regulation of interleukin-2.  Patients exposed to these drugs 
have increased risk of developing opportunistic infections (143) because of the non-
selective immunosuppression as well as the fact that skin flora may contain antibiotic-
resistant Staphylococcus aureus (144, 145).  Herein we propose to generate selective 
immuosuppression by exploiting a fundamental molecular difference between donor and 
recipient cells: class II MHC (MHC-II) molecules expressed by donor antigen-presenting 
cells (dAPCs).   
    Acute rejections are driven by mismatched class I and II MHC molecules expressed by 
donors and recipients whereby the latter mount potent T cell responses against skin 
allografts (54).  Allograft survival correlates with density of resident dAPCs.  Within 
hours following allogeneic skin transplantation, dAPCs residing within allografts begin 
migrating to host lymph nodes (146-148).  Once there, dAPCs activate allospecific T 
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cells via MHC and costimulatory molecules (7, 54).  Inside lymph nodes recipient CD4 
helper T cells recognizing mismatched MHC-II molecules are activated to drive CD8 T 
cell differentiation into cytotoxic T cells (CTLs) (Figure 4-1).  Presentation of MHC-II 
antigens is critical because generation of CTLs is compromised without CD4 T cell 
participation.  With visceral allografts, activation of CD4 and CD8 T cells are correlated 
with frequency of dAPCs in lymph nodes (149-151).  Skin dAPCs include donor 
Langerhans’ cells (dLCs) in the epidermis and dermal dendritic cells (dDCs).  dLCs and 
dDCs migrate in waves, with the trafficking complete within 4-5 days in rodent models 
(152).  Activated allospecific CD8 CTLs in turn migrate to the transplant site and damage 
graft parenchyma via recognition of MHC class I molecules (54).   The magnitude of 
rejection depends on the qualitative and quantitative encounter between dAPCs and 
recipient T cells shortly after grafting (152).   
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Figure 4-1 Schematic depiction of acute rejection of allograft.  Shortly after the 
transplantation, dAPCs in the allograft are activated (1) and migrate towards draining 
lymph nodes (2). Host T cells in the draining lymph nodes are activated via direct 
allorecognition by dAPCs (3). Activated T cells migrate to the allograft and mediate graft 
rejection (4). 
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    Because acute rejection is a function of dAPCs accumulating in recipient lymph nodes, 
methods have been devised to deplete dAPCs prior to transplantation.  Pre-clinical 
strategies tested so far have been non-specific in nature; typically the methods require 
systemic infusion of anti-leukocyte antibodies into donor animals before organ harvest 
(153-155).  While such preemptive strategies can be effective in delaying rejection of 
allografts in animal models, translation to humans is complicated by the ethical concerns 
and practicalities involved.  Recognizing the unmet need, we envisioned a new strategy 
by which dAPCs trafficking can be impeded selectively after transplantation.   
     Previously, we have discussed an injectable platform by which retention of IgG 
molecules in local tissues can be enhanced (chapter 3).  EAK16-II and related peptide 
amphiphiles are utilized in particular for their environmental responsiveness (156).  
These peptides undergo sol-gel phase transition at increasing ionic strengths; in deionized 
water, these peptides can be injected as solutions into physiological environment to 
establish gels in situ.  The injectable system localizes IgG molecules in vivo through 
directional binding (50, 123).  Membranes loaded with antibodies can be established in 
vivo by subcutaneous injection using hypodermic needled syringes.  Such immobilization 
partially overcomes antibody clearance mechanisms in tumors, as evidenced by the 
prolonged retention of IgG in mouse mammary and melanoma lesions (123).  In both 
tumor types, localized IgG remained in tumors significantly longer than free IgG.   
    In the present chapter, the in vivo performance of the system of materials to localize 
anti-MHC-II antibodies specific to dAPCs is demonstrated.  The rationale is that mixtures 
consisting of EAK16-II, its histidinylated analogue EAKIIH6, and intermediate proteins 
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(αH6-IgG and pAG) would localize the antibodies at the graft-host interface.  dAPCs 
migrating toward draining lymph nodes would interact with the antibody functionalized 
membranes, resulting in delayed and/or diminished encounter with T cells (Figure 4-2).  
The strategy was examined in the current study using an allogeneic mouse skin graft 
model.  All MHC alleles between the donor and recipient are mismatched, rendering this 
a stringent mode.  Consequently, we did not expect to observe delay in rejection by using 
the strategy alone.  The purpose of the work was to characterize the αI-Ad membrane in 
vitro and in vivo to assess feasibility of the concept instead of achieving full protection of 
the allograft.  To this end, we first investigated retention of a fluorescent-dye labeled IgG 
co-administered with the self-assembling components under normal and grafted skins.  
The immune responses toward the graft were then determined by analyzing T cell 
responses in recipient mice.  The data indicate that the platform can potentially become 
clinical tools that mitigate the magnitude of acute rejection of skin allografts.    
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Figure 4-2 Attenuation of T cell activity using anti-dAPCs membrane.   Antibodies 
targeting surface MHC-II molecules of dAPCs are displayed on the membranes of self-
assembling peptides EAK16-II and EAKIIH6 through intermediate proteins (αH6-IgG 
and pAG). Migrating dAPCs will be immobilized on the membrane due to the synergistic 
multivalent interactions between displayed anti-MHC antibodies and cell surface MHC-II. 
Hence, activation of host T cells through direct allo-recognition will be delayed or 
abolished. 
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Materials and Methods 
Materials 
Peptides were custom synthesized by American Peptide Company (Sunnyvale, CA) at 
greater than 95% purity with termini acetylated or amidated.  Peptides were reconstituted 
in sterile MilliQ water (18.2 M at 25C) at 5 mg/mL (3 mM, EAK16-II) or 7.5 mg/mL 
(3 mM, EAKIIH6).  Rabbit anti-His-tag polyclonal antibody (αH6-IgG, 0.2 mg/mL) was 
obtained from AnaSpec, Inc (San Jose, CA).  Recombinant protein A/G (pAG) was 
obtained from Pierce Biotechnology (Rockford, IL) and reconstituted to 0.25 mg/mL in 
sterile deionized water.   Anti-mouse I-Ad (MHC-II) antibody (αI-Ad, 0.5 mg/mL; clone: 
39-10-8) was purchased from Biolegend (San Diego, CA).  Allophycocyanin conjugated 
anti-mouse MHC-II I-Ad antibody (0.2 mg/mL) was obtained from eBioscience (San 
Diego, CA).  DyLightTM 800 conjugated goat anti-chicken IgG (IgG800) was obtained 
from KPL (Gaithersburg, MD) and reconstituted to 1 mg/mL in sterile deionized water.   
RPMI-1640 and fetal bovine serum (FBS) were obtained from HyClone (Logan, Utah).  
ACK lysing buffer and penicillin/streptomycin solutions were purchased from Lonza 
(Walkersville, MD).   
 
Skin transplantation 
Six–to-eight week old female (certified-virus-free) BALB/c and C57BL/6 mice were 
purchased from Charles River Laboratories (Wilmington, MA) and housed in the 
Duquesne University Animal Care Facility.   Animals were handled in accordance to 
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protocols approved by the Duquesne University Institutional Animal Care & Use 
Committee.  The transplant procedure was modified from a protocol described by Garrod 
et al (157) (Figure 4-3).  Briefly, the recipient C57BL/6 mice were anesthetized using 
isoflurane (induction: 5%; maintenance: 3%) and administrated with Bupernex at 0.1 
mg/kg intraperitoneally.  Ear skin explants (dorsal layer) were prepared from BALB/c 
mice and transplanted onto graft beds (each ~0.5 cm2) prepared in the flank of C57BL/6 
mice.  After surgeries, C57BL/6 mice were bandaged and recovered under infrared lamp. 
Their activities (food and water intake and mobility) were monitored regularly (157).   
 
Figure 4-3 Procedures of mouse skin transplantation. Dorsal ear skin of donor 
BALB/c mouse is grafted onto recipient C57BL/6 mouse. After recovery, the activities of 
recipient mice are monitored. Typically, allograft is rejected in about 10 days. 
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In vivo stability of IgG membrane in subcutaneous space and under the skin graft 
Anti-chicken IgG labeled with a near infrared dye emitting at 800 nm (IgG800) was used 
as a model antibody to investigate the assembling and stability of the system in vivo.  
EAK16-II (100 µg in 20 µL) was mixed with 37.5 µg (in 5 µL) of EAKIIH6. In a second 
vial, 2 µg αH6-IgG, 2 µg IgG800, and 0.375 µg pAG were mixed. The peptides and 
antibodies solutions were withdrawn into the same insulin syringe (28 G’ needle) and 
injected into the subcutaneous space in footpad or at flank of BALB/c mice.  
Fluorescence in the footpad was imaged ex vivo at 30 min, 6, 24, 48, and 72 h.  Footpads 
were collected and stretched out on a 15x100 mm dish using scotch tape for ex vivo 
imaging.  Images were captured using an Odyssey Imager (Li-Cor, Inc, Lincoln, NE) and 
measured at an intensity of 1.0 with focal distances of 3.2 mm and 3.5 mm.  
Quantification of fluorescent intensity was performed by drawing a polygon outlining the 
shape of the footpad.  The averaged signal of three blank footpads at each focal distance 
was subtracted as background.  Data reported represent intensities averaged from the 
measurement performed at each focal distance.  
    Signal at the posterior flank was recorded real time in vivo for up to 4 days. 
Anesthetization was induced using isoflurane (induction 5%, maintenance 3 %) for real 
time in vivo imaging.  Abdominal hairs were removed prior to scanning.  Mice were 
scanned prior to injection and monitored at the indicated times after injection using a 
Pearl Impulse imager (Li-Cor, Inc.). All images were collected using the same threshold 
and resolution (170 µm) settings.  Oval-shaped regions of interest were defined at the site 
of injection using the contralateral flank as background.  Fluorescence was quantified 
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using the Impulse (2.0) software (Li-Cor, Inc.) with a standard deviation multiplier of 10 
and a search limit of 100 pixels.  
    To demonstrate the assembling and stability of the system under the skin graft, the 
same amount of peptides and antibodies solutions were mixed and administrated onto the 
graft bed of C57BL/6 mice before the skin was placed.  Signal was monitored in real-
time using a Li-Cor Pearl Impulse Imager for up to 6 days as in the previous experiment.  
 
Detection of I-Ad+ dAPCs in draining lymph nodes 
The capability of anti-I-Ad membrane to impede the trafficking of dAPCs to host draining 
lymph nodes was studied using flow cytometry.  αI-Ad IgG with or without the antibody 
display system were administrated onto the graft bed prior to the skin graft.  Draining 
lymph nodes (inguinal, popliteal and axillary) were collected and pooled 1 day, 2 days, or 
3 days after transplantation.  Single cell suspensions were prepared by mechanical 
crushing and filtering through 70 µm nylon cell strainers.  APCs (both donor and 
recipient) were enriched using BD IMag mouse dendritic cell enrichment set (BD 
Bioscience, San Jose, CA).  APCs were re-suspended in 200 µL 3% FBS PBS.  Half of 
the cell suspension (100 µL) was stained with 2 µL allophycocyanin conjugated anti-
mouse MHC-II I-Ad antibody (4 µg/mL) by 1 h incubation at 4°C in the dark.  Unbound 
antibodies were washed away by centrifugation and resuspending in PBS three times.  
The other half, which serves as the unstained control, was treated with the same 
procedure but no staining antibody was added.  Samples were analyzed using a BD 
Accuri C6 flow cytometer (BD, Franklin Lakes, NJ) at 50,000 events per sample.   
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Allogeneic APC-T cells reaction 
To demonstrate that systemic T cell responses were attenuated, splenic T cells from 
recipient C57BL/6 were cultured with naïve BALB/c APCs. Six days after 
transplantation, the spleen was collected from BALB/c mice to prepare naïve APCs. 
Single cell suspension was prepared by dish crushing, hypotonic solution (ACK lysing 
buffer) treatment and filtering through a 70 µm nylon cell strainer. Cells were cultured in 
1 mL complete RPMI medium with 5 ng/mL GM-CSF at a density of 1 million/mL 
overnight.  Culture medium was gently pipetted to remove non-adherent cells.  Recipient 
C57BL/6 mice were euthanized and single cell suspension was prepared from the spleen 
at 0.5 million/mL.  C57BL/6 splenic T cells (1 million in 2 mL medium) were added into 
previously obtained naïve BALB/c APCs, and cultured for 48 h.  Cell culture medium 
was collected by centrifugation.  ELISA was used to quantify the concentration of IFN-γ 
(DuoSet mouse IFN-γ, R&D Systems, Minneapolis, MN) and IL-10 (DuoSet mouse IL-
10, R&D Systems) produced by recipient C57BL/6 T cells. 
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism 5.0.  Data were analyzed using one 
way ANOVA and Tukey-Kramer multiple comparison (α=0.05) or one-tailed Student’s t-
test (α=0.05) as indicated.  Data shown represent mean and standard deviation.  n 
indicates the number of animals in each group. 
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Results 
Mouse ear skin grafting is a robust method for measuring the magnitude of allograft 
rejection (158).  Excision of epidermal and dermal layers results in exposed underlying 
tissues that mimic debrided burnt skins (159).  The targets of the current strategy, dAPCs, 
are interspersed within skin layers of mouse and human (54).  LCs are immature DCs but 
promptly mature upon encountering alloantigens while migrating to secondary lymphoid 
tissues.  The density of these cells has been correlated with immunogenicity.  For 
example, mouse tail skin, which contains few LCs, is significantly less antigenic than ear 
skins (152).  We postulated that acute rejection can be attenuated by establishing 
materials that capture dAPCs at the graft-host interface (Figure 4-2).  
 
In vivo retention of IgG membranes in subcutaneous space  
To determine the ability of the system to localize antibodies in subcutaneous space in 
vivo, the fate of a NIR (=800nm) labeled IgG (hereafter “IgG800”) was tracked in 
BALB/c mice (Figure 4-4 and 4-5).  Superior stability was demonstrated by injecting the 
materials into the footpads of BALB/c mice subcutaneously (Figure 4-4).  Fluorescence 
could be detected for at least 72 h when IgG800 was injected with the assembling 
components, while IgG800 in saline (“Free IgG800”) was significantly lower at 6 h (p < 
0.001) and marginal after 24 h (p < 0.001) compared to the former.  Without pAG, 
retention of IgG800 was significantly lower at 6 h (p < 0.01), 24 h (p < 0.001), 48 h (p < 
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0.001) and 72 h (p < 0.001) compared to mice which received the antibody-membrane 
treatment.  This indicated molecular interactions involving pAG (123).  However, 
antibodies could still be non-specifically encapsulated into the fibrous structures of 
EAK16-II/EAKIIH6 without pAG, which explains the fluorescence observed when pAG 
was not added (system w/o pAG + IgG800).  Further evidence of localization was 
supported by real-time optical measurements.  When injected into the mouse flank, 
solutions containing IgG800 with self-assembling components showed remarkable 
localization (Figure 4-5).  Strong fluorescence was detected at the injection site for at 
least 96 h, while low fluorescence was observed with IgG800 in saline after 24 h.  Similar 
to previous intratumoral studies (Figure 3-9), there was a significant loss of antibodies in 
the first 24 h.  Therefore, full optimization may be necessary for maximal performance in 
the future.  Nonetheless, these in vivo results show that the self-assembling formulation 
was effective in retaining IgG locally.   
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Figure 4-4 Stability of the antibody display system in BALB/c mouse footpads.   (a) 
Representative ex vivo images of footpads injected with solution containing EAK16-II, 
EAKIIH6, αH6-IgG, pAG, and IgG800 (System + IgG800) or solution of EAK16-II, 
EAKIIH6, αH6-IgG, and IgG800 (System w/o pAG + IgG800) or IgG800 alone in PBS (Free 
IgG800).  All images were exported with the same settings from Licor Odyssey.  (b) 
Fluorescent intensity in footpads quantified in Odyssey.  Statistical significance 
(compared to System + IgG800) was analyzed by one way ANOVA with Tukey’s multiple 
comparison (0.5 h, 6 h, and 24 h) or student’s t test (48 h and 72 h) (n=5 for System + 
IgG800 and System w/o pAG + IgG800, n=3 for Free IgG800, ***: p < 0.001, **: p < 0.01). 
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Figure 4-5 Real time monitoring of antibody localization in vivo.   (a) Representative 
real time images of BALB/c mice injected with solution containing EAK16-II, EAKIIH6, 
αH6-IgG, pAG, and IgG800 (System + IgG800) or IgG800 alone in PBS (Free IgG800) at the 
lower flank.  All images were exported with the same settings from Licor Pearl Impulse. 
(b) Fluorescent intensity at the site of injection (n=2). 
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In vivo stability of IgG membranes under skin grafts 
Having established that the self-assembly process could take place in vivo in normal 
subcutaneous space, the ability of the system to localize at the site of allograft 
implantation was examined.  Membrane components mixed with IgG800 were established 
in the graft bed immediately prior to placement of allogeneic skins.  Fluorescence 
underneath the graft was monitored in live mice for 6 days (Figure 4-6).  IgG800 delivered 
with the assembling components showed superior localization.  As early as 5 minutes 
after injection, local fluorescent intensity (FI) registered at least two-fold higher than in 
mice received IgG800 without the components.  FI in mice received the antibody in 
membrane were significantly higher on day 3 (p < 0.01) and day 6 (p < 0.01) when 
compared to those in mice that received IgG800 in saline.  Bandages have to be removed 
during NIR imaging; however, premature removal of bandages would affect survival of 
grafts.  Therefore, mice were scanned only once on day 3 in addition to prior to 
bandaging (5 min) and after removal of bandages (day 6).  The system was able to retain 
antibodies more effectively at the host-graft interface compared to tumors and normal 
subcutaneous space.  Less than 50% fluorescent drop was observed even on day 3.  This 
slower clearance might result from limited fluid convection and impaired lymphatic 
drainage (160, 161).  These results indicated that the assembling components provided a 
mechanism by which IgG were retained at the graft-host interface.     
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Figure 4-6 Real time stability of antibody display system at the graft site.   (a) 
Representative real time images of recipient C57BL/6 administrated with solution 
containing EAK16-II, EAKIIH6, αH6-IgG, pAG, and IgG800 (System + IgG800) or IgG800 
  109 
 
alone in PBS (Free IgG800) at the graft bed prior to the skin graft.  All images were 
exported with the same settings from Licor Pearl Impulse.  (b) Fluorescent intensity at the 
graft site.  Student’s t test was used for statistical analysis at each time point (n=4 for 
System + IgG800 and n=3 for Free IgG800 due to one failed surgery, ***: p < 0.001, **: p 
< 0.01). 
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Evidence of impeded dAPCs trafficking to lymph nodes 
To determine the extent to which dAPCs trafficking was impeded by membranes loaded 
with anti-I-Ad IgG (hereafter I-Ad), draining lymph nodes (inguinal, axillary, and 
popliteal) of recipient mice were analyzed for the presence of I-Ad+ cells (Figure 4-7a).   
I-Ad IgG were placed on graft beds with or without the self-assembling components 
prior to grafting of ear skins.  At predetermined time points after transplantation, draining 
lymph nodes were excised from the mice after euthanization.  Lymph nodes from each 
mouse were pooled and stained for I-Ad+ cells.  Counting cells in draining lymph nodes 
serve as an indirect way to demonstrate that I-Ad+ cells are immobilized on the I-Ad 
membrane.  Evidence of co-localization of I-Ad+ and I-Ad membrane would further 
strengthen our conclusion.  The practical reason for not pursuing it is that the I-Ad 
membrane cannot be separated from the graft or the host tissue for histology studies.  
Flow cytometric analyses indicated that on day 2 I-Ad membrane-treated C57BL/6 mice 
had 2.0% (±0.18) of dAPCs in draining lymph nodes, significantly lower (p < 0.05) than 
that of C57BL/6 mice received I-Ad delivered in saline (3.5%±0.52; Figure 4-7c).  I-
Ad membrane-treated C57BL/6 mice showed lower (but not significantly different) 
frequency of I-Ad+ cells on day 3 (Figure 4-7d).  The two groups showed comparable 
frequency of I-Ad+ cells on day 1 (Figure 4-7b).   
    Statistical significance of dAPCs frequency in draining lymph nodes was observed 
only on day 2. One potential reason for that is the lag time for complete assembly of αI-
Ad membrane due to limited fluid and salts in graft beds.  According to Larsen et al., 
there are 921 ± 204 epidermal Langerhans cells (LCs) per mm-2 in a skin graft on day 0 
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after transplantation (152).  The density dropped to 370 ± 128 per mm-2 on day 1, then to 
293 ± 110 per mm-2 on day 3, and eventually to 128 ± 105 per mm-2 on day 7.  Thus, 
upon placement of skin graft, dAPCs immediately migrated out (within the first few 
hours) may have escaped the αI-Ad membrane, which is not fully assembled. The effect 
seen on the second day may result from impeded trafficking from a second wave of 
emigrated dAPCs.  Taken together with the in vivo stability studies, these results 
indicated that enhanced localization of the anti-MHC-II antibodies was able to impede 
the trafficking of dAPCs.      
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Figure 4-7 Detection of I-Ad dAPCs in draining lymph nodes by flow cytometry.  αI-
Ad IgG was administrated at the graft bed with the self-assembling components (αI-Ad 
membrane) or PBS (αI-Ad IgG, local) prior to the skin graft. Single cell suspension was 
prepared from draining lymph nodes of recipient C57BL/6 mice and dendritic cells were 
enriched.  Cells were stained with Allophycocyanin conjugated anti-mouse MHC-II I-Ad 
antibody, and flow cytometry was used to probe the frequency of I-Ad dAPCs.  (a) 
Representative flow cytometry histogram of dAPCs frequency at day 2 (unstained sample 
and stained samples from each group). Student’s t test was used to confirm the statistical 
difference on day 1(b, n=4, ns: not significant), day 2 (c, n=4 for αI-Ad membrane and 
n=3 for αI-Ad IgG, local, *: p < 0.05), and day 3 (d, n=3, ns: not significant). 
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Suppression of T cell responses in recipient mice 
We next hypothesized that reduced dAPCs trafficking would manifest in altered systemic 
T cell responses toward the allograft.  To test this, T cells of recipient mice were analyzed 
ex vivo to evaluate immune reactivity toward donor antigens.  Lymphocytes isolated from 
spleens harvested from transplanted animals were stimulated in vitro by culturing with 
fresh leukocytes from naïve donor mice (Figure 4-8a).  After 48 h, culture supernatants 
were analyzed using ELISA to determine the concentrations of IFN-, a characteristic 
cytokine produced by activated T cells in cell-mediated rejection.   
The results indicated that mice received I-Ad membrane yielded T cells that were 
hypo-responsive.  Splenic T cells recovered from mice received I-Ad  membrane 
produced 4.4 ng/ml (±1.7) IFN-γ, in contrast to 15.1 ng/ml (±3.4) and 22.1 ng/ml (±5.1) 
from mice received only I-Ad in saline (I-Ad IgG , local; p < 0.01) or the amphiphilic 
peptides (EAK16-II/EAKIIH6; p < 0.001), respectively.  T cells from transplanted mice 
administered with the peptide amphiphiles without I-Ad produced high levels of IFN-.  
Low levels of IFN- were released from T cells from mice transplanted with isografts 
(C57BL/6 ear  C57BL/6 hosts) in which no rejection was expected (Figure 4-8b).  
Generally low levels of IL-10 were detected in all groups with T cells from the mice (< 
200 pg/ml).  Co-cultures from mice treated with the system were found to have less IL-10 
than the rest (Figure 4-8c).  Collectively, the differential cytokines produced by recipient 
T cells support the notion that T cell responses were attenuated specifically with local 
depositions of I-Ad membranes. 
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It is noticeable that cells in “Irrelevant IgG” control group produced lower 
concentrations of IFN-and IL-10 compared to other control groups.  One possible 
explanation is cross-linking of anti-His-tag antibodies.  EAK16-II and EAKIIH6 co-
assembles into a fibrous network with His-tags appending on fibrils.  Anti-His-tag 
antibodies have two Fab domains (binding sites). When each Fab binds to a His-tag on 
two different fibrils, fibrils are efficiently cross-linked, resulting in a denser network with 
smaller pores.  The fibrous network functions as a barrier to migration of dAPCs, which 
could be impeded when the network becomes denser.                     
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Figure 4-8 Concentration of IFN-γ and IL-10 produced by recipient C57BL/6 mouse 
splenic T cells cultured with naïve BALB/c APCs.   Treatments were administrated to 
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the graft bed prior to the skin graft: αI-Ad membrane (EAK16-II, EAKIIH6, αH6-IgG, 
pAG, and αI-Ad IgG), αI-Ad IgG, local (αI-Ad IgG in PBS), EAK16-II/EAKIIH6 
(EAK16-II and EAKIIH6), Irrelevant IgG (EAK16-II, EAKIIH6, αH6-IgG, pAG, and 
anti-I-Ab IgG), and Saline (isotonic saline solution).  αI-Ad IgG, I.V. represents αI-Ad IgG 
administrated through tail vein.  Isograft indicates C57BL/6 to C57BL/6 transplantation. 
(a) Schematic of the experimental procedures. 7 days after the transplantation, T cells 
were prepared from spleen of recipient C57BL/6 mice and cultured with naïve BALB/c 
mouse APCs.  The cell culture medium was collected by centrifugation and 
concentrations of IFN-γ and IL-10 were quantified by ELISA.  (b) Concentration of IFN-
γ produced by recipient C57BL/6 mouse splenic T cells.  (c) Concentration of IL-10 
produced by recipient C57BL/6 mouse splenic T cells. One way ANOVA with Tukey’s 
multiple comparison was used for statistical analysis (n=5 for αI-Ad membrane, n=6 for 
αI-Ad IgG, local, n=3 for EAK16-II/EAKIIH6, n=4 for αI-Ad IgG, I.V., n=3 for Irrelevant 
IgG and saline, n=4 for Isograft, ***: p < 0.001, **: p < 0.01, *: p < 0.05, ns: not 
significant, compared to αI-Ad membrane group,). 
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Discussion 
The two mouse strains tested here express distinct sets of class II MHC molecules: I-Ad 
and I-Ed (BALB/c), and I-Ab (C57BL/6).  These antigenic mismatches drive a robust 
rejection regime.  In C57BL/6 recipients, T cells exist to recognize I-Ad and I-Ed on 
dAPCs to develop into IFN-driven cytotoxic responses.  These reactions are sustained 
by dAPCs (Figure 4-1).  When placed in vivo, dAPCs migrate from skin explants to 
stimulate recipient T cells in regional lymph nodes and ultimately populate the rest of the 
host.  The extent of anti-graft T cell activation correlates with MHC-II+ dAPCs migrated 
to graft-draining lymph nodes (54).  Donor MHC antigens (released by dead graft cells) 
are also presented by graft-infiltrated host APCs (hAPCs).  While this form of indirect 
recognition contributes to rejection (7),  the initial rejection intensity depends on dAPCs.   
    In spite of high dose calcineurin inhibitors (cyclosporine A and tacrolimus) and 
corticosteroids, skin allografts are difficult to sustain owing to their heightened 
antigenicity.  Attenuating acute rejection of skin-derived allogeneic antigens would 
improve the viability and functions of such transplants as wound dressings.  Local-
regional delivery of immunosuppressants was first attempted by Billingham in 1951 
(162).  Using cortisone acetate in a topical formulation the investigators were able to 
prolong skin allograft survival in a rabbit model.  Importantly, the same dose, which was 
relatively low, was ineffective when administered systemically.  The next documented 
attempt came 35 years later when another group applied topical cyclosporine A (CSA) 
formulated in DMSO to rats received skin allografts (163).  While long-term graft 
survival was attained, interpreting results of the topical strategy was complicated by the 
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large dose used (5 mg per kg daily).  The authors noted significant systemic drug 
absorption.  In general, the rationale for topical delivery of calcineurin inhibitors and 
steroidal anti-inflammatory drugs are weakened by their lipophilicity and penetration 
through the stratum corneum.   Furthermore, Zhao and colleagues have reported bacterial 
infiltrates in skin allografts of rats received topical CSA and fluocinolone acetonide (164).   
Thus local drug delivery per se does not necessarily circumvent toxicities (165).  Rather 
than suppressing recipient leukocytes, depleting dAPCs may impute a targeted 
mechanism to attain specific immunosuppression.          
Depleting dAPCs in allografts has been explored as a potential anti-rejection therapy 
previously.  Odling and coworkers treated donor skins ex vivo with low-dose ultraviolet 
light radiation or chemical carcinogens prior to grafting in mice to reduce dAPC activity 
(166, 167).  Depletion has also been done using anti-cell antibodies and genetically 
engineered mice or precursor cells (153-155).  Moreover, skin grafts live longer when 
lymphatic drainage is temporarily impeded (168, 169).  These and similar methods 
blocking dAPC trafficking are difficult to translate to humans.  An unmet need is a 
formulation by which trafficking of donor leukocytes can be intercepted in recipient hosts.  
Herein evidence supporting a local strategy that builds upon self-assembling materials is 
presented.  The goal is to target unique cell surface molecules on donor immune cells that 
drive acute rejection mechanisms.   
    The rejection of grafts correlates with the density of dAPCs; each dendritic cell (DC, 
the most potent APC) is able to activate 100-3,000 T cells (170).  Immature DC is 6-9 µm 
in size, smaller than mature ones (15 µm) (171).  Mature dendritic cells will upregulate 
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the expression of MHC-II molecules, which increase from about 40,000 to 200,000 per 
cell (172, 173).  In skin transplantation, a skin graft of 0.5 cm × 1 cm was used, which 
may contain about 50,000 dAPCs.  An initial dose of 1.33 × 10-5 µmole antibodies (8 × 
1012 IgG molecules) were administrated, more than half of that could be considered to be 
stably displayed as the fluorescent intensity on day 3 was still higher than half of the 
initial fluorescence (Figure 4-6).  The number of antibodies displayed (4 × 1012 IgG 
molecules) exceeds the number of MHC-II molecules (4 × 1010).  Therefore, the anti-
dAPC membrane might be able to immobilize all dAPCs in theory.   
The anti-dAPCs membrane was shown to form in situ, in both normal skins and on 
transplant graft bed.  The membranes remained in place for 6 days, exceeding the kinetics 
of dAPCs emigration from ear skins, which peaks on day 5 in vitro (152).  Attenuation of 
allograft-specific T cell responses in recipients was demonstrated (Figure 4-8).  Without 
the I-Ad membrane system, T cells harvested from spleens strongly reacted toward 
donor antigens, as evidenced by the high concentrations of IFN- produced ex vivo.  But 
mice treated with the I-Ad membrane showed general hypo-responsive T cells evident 
in low IFN- and IL-10 production.  Studies have shown that increased IL-10 would 
indicate tolerance towards the allografts.  Expansion of IL-10-producing regulatory T 
cells would require inflammatory or immune modulation (174, 175).  It should be noted 
that all transplanted skins were rejected (scored based on gross necrosis) by day 10.  This 
was not unexpected given the extent of MHC disparities.  In addition, the flow data 
indicates some dAPCs were able to circumvent the αI-Ad membrane and reach the 
draining lymph nodes.  Therefore, some host T cells will still be activated through direct 
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allorecognition.  Nevertheless, the data presented herein demonstrated the utility of an 
anti-MHC-II material system in mitigating skin allograft rejection.  Taken together, the 
data support the hypothesis that anti-MHC-II membrane can attenuate acute rejection by 
impeding trafficking of dAPCs to secondary lymphoid tissues.  
 
Conclusions  
The biological functionality, i.e. immune modulation, of the antibody display system has 
been demonstrated in a murine skin transplantation model. In this model, the acute 
rejection of allograft is mediated through emigrating dAPCs (MHC-II: I-Ad), which 
activate T cells by direct allorecognition.  Using NIR fluorescence dye labeled IgG, 
antibodies could be stably displayed in the graft bed as well as subcutaneous space in 
healthy mice.  When anti-I-Ad IgG were displayed, the resultant anti-dAPCs membrane 
was able to impede the trafficking of dAPCs to host draining lymph nodes.  As a result, 
systemic T cell responses were attenuated indicated by the lower production of IFN-γ. 
The mouse skin transplantation (BALB/c to C57BL/6) is a stringent model widely 
employed in development and validation of immunosuppressants (176).  Mouse ear skin 
contains high density of residing APCs, and the strength of acute rejection correlates with 
number of dAPCs.  For example, mouse ear skin is much more antigenic than mouse tail 
skin as the latter contains very few LCs (152).  Because of the distinctive mismatched 
MHC-II molecules, we did not expect prolonged survival of graft from rejection.  
However, our studies demonstrated the feasibility of attenuating host T cell activity by 
intercepting migrating dAPCs.   
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The antibody display system is versatile and injectable, and it may be transferred to 
other transplantation models, such as liver and kidney transplantation.  Mouse solid 
organs also have a high number of DCs.  For instance, heart, kidney, pancreas, and liver 
of C57BL/10 mouse have 400,000, 650,000,  350,000, and 3,000,000 DCs respectively 
(177), which results to strong acute rejections.  The anti-dAPC membrane may be 
administrated at the graft-host interface.  Compared to skin transplant, solid organs have 
more blood supply and tissue fluid, which may accelerate the assembly process.  A fully 
assembled anti-dAPC membrane might capture dAPCs more efficiently considering the 
fact that dAPCs starts to migrate within hours after the surgery. 
Although it was not further pursued in my dissertation project, evidence of co-
localization of anti-dAPC membrane and dAPCs would strengthen our conclusion that 
trafficking of dAPCs was impeded.  This may be achieved by pre-labeling dAPCs ex vivo, 
for instance, using dual imaging nanoemulsions (178-180).  Therefore, migration of 
dAPCs could be tracked real time.   
Besides acute rejection driven by dAPCs, hAPCs could also activate T cells after 
uptake and presentation of donor antigens, i.e. chronic rejection (1).  One advantage of 
our system is versatility.  Antibodies targeting different antigen could be co-displayed on 
the membrane in situ.  To translate this strategy into clinical therapies, it may be used in 
combination with immune suppressants.  Antibodies targeting cell surface molecules of 
both dAPCs and hAPCs could be co-displayed.  By disrupting the trafficking of APCs of 
both traits, doses of immune suppressants may be reduced as well as unwanted side 
effects.    
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CHAPTER 5  
Co-assembly of Amphiphilic Peptide EAK16-II with Histidinylated 
Analogues and Implications for Functionalization of β-sheet Fibrils in 
vivo 
In Chapter 3 and Chapter 4, a prototype formulation of the antibody display system 
(Table 1-2), which was developed based on pilot studies, was used to demonstrate in vivo 
performance.  To advance this system into clinical applications, the formulation has to be 
fully optimized.   EAK16-II/EAKIIH6 co-assembly functions as the base of antibody 
display system.  Understanding how the two peptides co-assemble would provide insight 
in optimizing the system in the future.  As a step towards next stage development, the 
EAK16-II/EAKIIH6 co-assembly was characterized and discussed in the current chapter.   
 
Abstract 
EAK16-II is one of first building blocks of environmental responsive materials.  This 
self-assembling peptide undergoes solution-to-gel transition when transferred from low to 
high ionic strength environment.  Previously we have demonstrated the histidinylated 
analogue EAKIIH6 co-assembles with the parent peptide to render His-tags as a 
functionalization mechanism in vitro and in vivo.  The present chapter aimed to 
understand the pathways by which the analogue co-assembles with EAK16-II. The results 
presented herein suggested two competing but not mutually exclusive events in the co-
assembly.  Gel electrophoretic data showed that EAKIIH6 self-sorted to high molecular 
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weight species without EAK16-II.  Spectroscopic analysis indicated that these high 
molecular weight species consisted of both α-helices and β-strands.  Self-sorting of 
EAKIIH6 was inhibited by the parent peptide in a concentration dependent manner.  
Injecting mixtures containing EAKIIH6 subcutaneously rendered His-tags detectable in 
live mice for at least 312 h, despite diluting the histidinylated analogue by 10 to 50 folds 
compared to a previous formulation (4:1 in chapter 3).  The study provided a formulation 
by which in vivo display of His-tags was attained without excess amphiphilic peptides.  
By increasing co-assembling efficiency, the likelihood of generating immunogenic 
aggregates outside the main fibrils could be minimized.  These findings provide insights 
for rational functionalization of in situ self-gelling materials. 
 
Introduction 
β-sheet fibrillizing peptides are versatile building blocks of drug delivery systems and 
tissue engineering scaffolds (38, 156, 181, 182).  The EAK16 series of low molecular 
weight peptides form cross- fibrils on which cell attachment and differentiation are 
supported (57).  These in situ-forming -fibrils can be functionalized for biomedical 
applications (156).  Bioactive amino acid motifs can be synthesized in tandem with self-
assembling domains while preserving self-assembly and hydrogelation through ionic-
complementarity (28).  This strategy has been used to control cell attachments by 
embedding within amphiphilic sequences with biological ligands (27, 34).  An alternative 
approach is to drive co-assembly of two ionic complementary peptides of which one 
contains a functional domain (50, 123, 183, 184).  An advantage of this approach is that 
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the bioactive motif is structurally decoupled from the fibrillizing domain, thereby 
allowing mutual optimization of both traits.   
    We have previously characterized the properties and functions of cross- fibrils 
formed by admixing EAK16-II with its C-terminal histidinylated analogue EAKIIH6.  
Both peptides contain an amphiphilic domain with alternating hydrophilic and 
hydrophobic amino acids.  The ionic-complementarity drives co-assembly of the two.  
Introducing His-tags provides a versatile docking mechanism; it transforms the 
fibrillizing module into a platform on which diverse therapeutic proteins can be anchored 
via nickel coordination or non-covalent protein-protein interactions.  We have previously 
demonstrated utility of the latter using anti-His-tag antibodies (H6-IgG) and protein 
A/G (pAG).  The specificities and high affinities of anti-His-tag antibodies for 
consecutive histidines and pAG for IgG Fc domain collectively render a reliable linking 
regime.  Displayed antibodies proved biologically active.  When injected into living mice 
the antibody-material assemblies remain stable at the injection site for at least 5 days.  
We envision this system can be used for modulation of local immune milieu at the same 
time minimizing systemic toxicities.  Antibodies targeting soluble antigens or cell surface 
markers can be localized in tumors or other inflammatory locales to steer immunological 
reactions toward favorable outcomes (chapter 3 and 4). 
    The low viscosity of the peptide-protein mixture in deionized water allows injection 
via conventional needled syringes.  In our experimentations, the two peptides were 
intermixed in deionized water before fibrillizing in salt solutions or in vivo.  Gasiorowski 
and Collier showed such mixing sequence results in gels with superior cell adhesion 
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capacity in vitro (185).  In their study, Q-11-based peptides (sequence: QQKFQFQFEQQ) 
were formulated in 10:1 molar ratio, with functionalized (RGD) peptide as the lesser of 
the two.  In our studies, when formulated at 4:1 molar ratio, the EAK16-II/EAKIIH6 co-
assembly stably displays His-tags in vitro (50).  When injected into mice subcutaneously, 
the same formulation localizes His-tags at the injection site for up to 11 days (Figure 3-6).        
    An advantage of employing the co-assembly strategy is that His-tags (EAKIIH6) can 
be introduced into emergent materials without compromising gelation (EAK16-II).  The 
ability to tune the amount of His-tags independently provides a way to tailor the design 
for specific applications.  However, the notion that His-tags can be optimized by simply 
changing the relative fraction of EAKIIH6 warrants close examination.  The efficiency of 
the co-assembly depends on two competing but not mutually exclusive events: EAKIIH6 
may associate with other EAKIIH6 molecules (self-sort), and/or with EAK16-II (co-
assembly).  Based on molecular modeling studies it was postulated that EAKIIH6 
intercalates into EAK16-II -sheets (50).  The present study aimed at understanding the 
mechanisms by which EAKIIH6 are driven into EAK16-II fibrils.  The co-assembling of 
EAK16-II and EAKIIH6 in vitro and in vivo was interrogated experimentally in this 
chapter.  Insights gained from in vitro studies guided in vivo delivery formulation efforts.    
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Materials and Methods 
Peptides and reagents 
All peptides were custom synthesized by American Peptide Company (Sunnyvale, CA) at 
greater than 95% purity with termini acetylated or amidated.  Peptides were reconstituted 
in sterile MilliQ water (18.2 M at 25C) at 5 mg/mL (3 mM, EAK16-II, AcNH-
AEAEAKAKAEAEAKAK-CONH2) or 7.5 mg/mL (3 mM, EAKIIH6 or EAKIVH6: 
AcNH-AEAEAEAEAKAKAKAKHHHHHH-CONH2), or 7.2 mg/mL (3 mM, VHAH6: 
AcNH-VHASHAVHAAHAVHAHHHHHH-CONH2).  Rabbit anti-His-tag polyclonal 
antibody (αH6-IgG, 0.2 mg/mL) and fluorescein conjugated Rabbit anti-His-tag 
polyclonal antibody (αH6-IgGFITC, 0.2 mg/mL) were purchased from AnaSpec, Inc (San 
Jose, CA).  DyLight 800 conjugated goat anti-rabbit IgG (Rabbit-IgG800; 1 mg/mL) was 
purchased from Pierce Biotechnology (Rockford, IL). 
 
Gel electrophoresis 
SDS-PAGE was used to probe whether EAKIIH6 would precipitate.  The peptide was 
dissolved in PBS at 0.0015, 0.003, 0.006, 0.015, 0.03, or 0.06 mM.  Supernatants were 
analyzed using denaturing conditions in NuPAGE 4-12% Bis-Tris gels (Life 
Technologies, Carlsbad, CA) before and after centrifugation (relative centrifugal force 
(rcf) = 16,000g for 10 min).  Peptide aggregates were identified using native gel 
electrophoresis.  EAKIIH6 (0.015 μmol in 5 μL) was added to 45 μL of PBS buffered at 
different pH for 2 h at 37C.  Supernatants were run on NativePAGE 4-16% Bis-Tris gel 
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(Life Technologies).  To quantify the co-assembly efficiency, 0.015 μmol (in 5 μL) of 
EAKIIH6 (or EAKIVH6 or VHAH6 as related analogues for comparison) was mixed 
with 4, 8, 16 or 32-folder higher moles of EAK16-II before adding into PBS to a final 
volume of 500 μL.  EAKIIH6 (0.015 μmol) alone was included as a standard.  After 
incubation at room temperature for 2 h allowing for precipitates to settle under gravity, 
supernatants were analyzed using denaturing NuPAGE 4-12% Bis-Tris gel (Life 
Technologies).  Proteins were visualized using SilverQuest staining (Life Technologies) 
with a reported detection limit of 0.3 ng.  Images were taken using the Kodak 440 Image 
Station (Rochester, NY) and band intensity was quantified using ImageJ (version 1.45s). 
 
Fluorescent measurement and microscopy  
To probe His-tag accessibility, 0.12 μmol (in 40 μL) of EAK16-II was mixed with 
different amounts of EAKIIH6 (or EAKIVH6 or VHAH6) to generate different ratios of 
the two.  The premixed peptide solution was added PBS to a final volume of 1 mL into 
which 20 μg of αH6-IgGFITC was added.  Co-precipitates were rinsed and collected by 
centrifugation at 15,000g for 10 min.  The pellets were then transferred to a 96 well plate 
in which fluorescent intensity was measured using a Perkin Elmer VICTOR 1420 reader 
(Perkin Elmer, Waltham, MA). Images of the same samples were captured using a Vista 
Vision inverted microscope (VWR, Radnor, PA) equipped with a ProgRes C3 cooling 
CCD camera (Jenoptik AG, Jena, Germany). 
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Spectroscopic analyses of peptide conformations 
Fourier-transformed infrared (FT-IR) spectroscopy was performed using desiccant-dried 
samples of 0.06 μmol (in 20 μL) EAKIIH6 dissolved in 80 μL of PBS.  FT-IR spectra 
were recorded on a Thermo Nexus 470 Infrared Spectrometer using an attenuated total 
reflectance (ATR) cell operated at a spectral resolution of 4 cm-1 over 256 scans. The 
spectra were processed in OMNIC software (Thermo Scientific) for automatic baseline 
correction and smoothing, after which the second derivative was calculated.  To obtain 
the CD spectra, 0.015 μmol (in 5 μL) of EAKIIH6 was added into 195 μL PBS with 
different pH: 1, 3, 5, 7, 9, and 11.  After 2 h incubation at room temperature, CD spectra 
of samples were recorded from 180 nm to 260 nm on a Jasco J-810 spectropolarimeter 
(Jasco Analytical Instruments, Germany). The signal was collected on 0.1 nm intervals 
and averaged by 7 runs. After background correction, absorbance values were converted 
to mean residue ellipticities.  Percentage of secondary conformations was evaluated using 
CDPro algorithms (186) based on reference protein data set no. 3.  The results 
represented an average of three deconvolution algorithms (SELCON3, CONTINLL, and 
CDSSTR). 
 
Mice and in vivo clearance  
Six to eight week old female (certified-virus-free) BALB/c mice were purchased from 
Charles River Laboratories (Wilmington, MA) and housed in the Duquesne University 
Animal Care Facility.  Animals were handled in accordance with protocols approved by 
University Institutional Animal Care & Use Committee. The injection mixtures contained 
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0.12 μmol (in 40 μL) of EAK16-II added with different ratios of EAKIIH6 (or EAKIVH6 
or VHAH6).  In a separate vial, 20 g of a rabbit-derived αH6-IgG was mixed with 20 g 
goat anti-rabbit Dylight-800 conjugated IgG.  The two mixtures were drawn into the 
same syringe (28 G’ needle) and injected subcutaneously into the lower flank of mice.  
Abdominal hairs were removed prior to imaging using a Pearl Impulse imager (Li-Cor, 
Inc.) while mice were anesthetized with isoflurane (induction 5%, maintenance 3%).  All 
images were captured at the same threshold and resolution (170 µm) settings.  Oval-
shaped regions of interest were defined at the site of injection with contralateral flank as 
background.  Fluorescence intensity was quantified using the Impulse software (Li-Cor, 
Inc.) with a standard deviation multiplier of 10 and a search limit of 100 pixels.  
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism 5.0.  Data were analyzed using 
one-way ANOVA and the Tukey-Kramer pairwise multiple comparison test (α=0.05).  
Data shown represent mean and standard deviation.  Power analysis is used to determine 
the sample size of the in vivo studies (n=4).  For comparison of mice treated with 
EAK16-II, EAKIIH6, PBS, or EAK16-II/EAKIIH6, an n of 4 yields 1-β greater than 0.99.  
n indicates number of replicates/animals in each group. 
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Results 
Self-sorting of EAKIIH6  
Understanding the competing events of co-assembly and self-sorting (either self-
assemble into fibrils or form unordered aggregates) is imperative for rational design of 
multi-component fibrillar materials.  It has been shown that EAKIIH6 by itself was not 
able to self-assemble into macroscopic fibrous structures both in vitro (Figure 3-2c) and 
in vivo (Figure 3-7). As expected, high-density materials were not found in EAKIIH6 
below or above the critical assembling concentration (CAC) of EAK16-II (CAC = 0.1 
mg/mL) (72); all peptide dissolved at 1.5-60 M in PBS remained in supernatants after 
centrifugation (Figure 5-1a).  Although no insoluble macroscopic structure had been 
observed, native gel electrophoretic data revealed that EAKIIH6 at a concentration of 0.3 
mM formed oligomers in acidic, neutral and alkaline buffers (Figure 5-1b); multiple 
species weighing between 240 to 480 kDa and beyond 720 kDa were found in non-
denaturing gels.  These aggregates corresponded to from 100 to 300 EAKIIH6 peptides 
(MW = 2.48 kDa).  These data revealed the intrinsic propensity of EAKIIH6 to self-sort 
into multimeric structures.   Nonetheless, EAKIIH6 was not able to form insoluble 
membrane by itself even at high pH.  His-tags would disrupt the hydrophobic interactions 
of alanines if they are part of stacked β-sheets, therefore, they may have to extrude 
outwards of β-sheet.  On the other hand, these appending His-tags could still destabilize 
EAKIIH6 β-sheets due to steric expulsion.   
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Figure 5-1 Non-precipitation and self-sorting of EAKIIH6.   (a) Denaturing PAGE of 
supernatants from EAKIIH6 buffered saline samples centrifuged (“C”; 16,000 rcf) and 
non-centrifuged (NC); (b) Native PAGE image of EAKIIH6 dissolved in PBS (0.3 mM) 
after incubation.  Figure adapted from reference (187) with permission. 
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Conformations of EAKIIH6 
We next determined if the EAKIIH6 species revealed in native PAGE were -fibrils. We 
have previously shown that the amyloid-specific chromogenic dye Congo red fails to 
bind EAKIIH6 (Figure 3-2c).  To probe the nature of these higher-ordered structures, 
ATR FT-IR was used to determine the peptide conformational ensemble in air-dried 
samples of EAKIIH6 dissolved in PBS.  Second derivatives revealed the presence of -
helix structure as indicated by the peak at 1649 cm-1.  The peaks at 1630 cm-1 and 1622 
cm-1 revealed the presence of β-strands and -sheets (Figure 5-2a) (188, 189).  These 
spectral features resembled those found in the spectra of EAK16-II, but the peak at 1622 
cm-1 was weaker in the EAKIIH6 spectrum.  The intense peaks at 1641 cm-1 and 1670 
cm-1 in the EAKIIH6 spectrum suggested the presence of unordered structures and β-
turns, respectively.  The dominance of -helix in EAKIIH6 was supported by circular 
dichroism in which spectrum of the peptide showed double minima at 208 and 222 nm, 
typical of -helix conformation.  Intensities of these transitions changed at varying pH 
(Figure 5-2b).  Deconvolution revealed dominant -helix (~35%) between pH 1 to pH 7 
(Figure 5-2c).  The pattern reversed when pH rose above 9, at which -strand increased 
to 22%, apparently at the expense of -helix (26%).  The -helix to -sheet transition 
coincided with deionization of the histidines.  Most of the imidazoles (assumed histidine 
pKa = 6.10) would be unionized at pH 9.   
While the CD data indicates α-helix was the dominating conformation for EAKIIH6, a 
stronger peak at 1622 cm-1 (compared to 1649 cm-1) in FT-IR spectrum implies a 
relatively higher content of β-strand conformation.  This difference may arise from 
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different sample preparation protocols.  CD spectrum was collected with EAKIIH6 
dissolved in PBS which reflects conformations in solution states.  In FT-IR studies, 
peptides were incubated in PBS first and dried.  As water is being removed, peptides may 
re-organize to different structures.  Nonetheless, these data suggested a plasticity of 
EAKIIH6 conformational ensemble in which -helix and -strand coexisted.  The 
findings supported a previous postulation that while EAKIIH6 generally adopts a -helix 
conformation, it could be forced into -strands (50).       
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Figure 5-2 Conformational properties of EAKIIH6 aggregates.   (a) Second 
derivative FT-IR spectra of desiccant-dried EAKIIH6 and EAK16-II dissolved in PBS 
(0.6 mM); (b) circular dichroism spectra of EAKIIH6 (0.075 mM) at different pH; 
absorbance values were converted to mean residue ellipticities. (c) Percent α-helix and β-
strand of EAKIIH6 revealed by deconvolution using CDPro.  Figure adapted from 
reference (187) with permission. 
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Dilution of EAKIIH6 in EAK16-II  
The observation that EAKIIH6 self-sorted into higher-ordered species instructed how the 
peptides were formulated for in vivo applications.  We postulated that at above a certain 
relative amount, EAK16-II inhibits self-sorting of EAKIIH6, providing a rationale for 
maximizing co-assembly efficiency.  To test this, the extent of co-assembly was 
examined by mixing the two at different molar ratios.  The fraction of EAKIIH6 was held 
constant while varying EAK16-II, with the latter added at 4, 8, 16 and 32-fold higher 
concentrations.  Co-assembled peptides would precipitate and un-incorporated peptides 
would remain in supernatant.  Using SDS-PAGE it was found that at all ratios tested, no 
EAK16-II was detected in the supernatant and therefore precipitated completely (data not 
shown).  Diluting EAKIIH6 with EAK16-II increased the efficiency of the co-assembly 
(Figure 5-3a).  At relatively low excess of EAK16-II (4:1 and 8:1), less than 40% of 
EAKIIH6 co-precipitated into fibrils.  Raising EAK16-II amount to 32:1 resulted in close 
to 95% of EAKIIH6 precipitating (Figure 5-3b).  These data indicated that the presence 
of abundant EAK16-II inhibited self-sorting of EAKIIH6.  Increasing the relative amount 
of EAK16-II increased the efficiency of co-assembling.  Taken together, excess 
EAKIIH6 in the low efficient mixtures (4:1 and 8:1) most likely diverted into aggregating 
byproducts outside the main fibrils generated from co-assembly. 
    Two other His-tagged peptides were studied for comparison (Figure 5-4a).  When 
mixed with EAK16-II, VHAH6 co-precipitated poorly (Figure 5-3c). VHAH6 was shown 
in circular dichroism adopting random coils in neutral phosphate buffers (Figure 5-4b).  
The incorporation at higher EAK16-II ratios (16:1 and 32:1) may result from non-specific 
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entrapment and adsorption of VHAH6 aggregates.  Conversely, EAKIVH6 incorporated 
efficiently with EAK16-II (Figure 5-3d).  This peptide adopted a weak -helix 
conformation (Figure 5-4b), although the parent EAK16-IV adopts a hairpin/-turn 
configuration, owing to intra-peptide charge pairing (67).  The offset in charge patterns in 
the amphiphilic segment between EAK16-II (--++--++) and EAKIVH6 (----++++) did 
not preclude their co-precipitation (Figure 5-3d).  These data indicated that peptides 
containing amphiphilic domain in -helical conformation could participate in 
fibrillization.  Ionic pairing among -sheets in the fibrils appeared flexible.  EAKIVH6 
could slide along the EAK16-II -sheet horizontal plane to locate lateral hydrogen bonds 
while minimizing charge repulsion.   
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Figure 5-3 Co-assembly efficiency as a function of molar ratios of EAK16-II to 
histidinylated peptides.   (a) Representative image of unincorporated EAKIIH6 from 
mixing with EAK16-II; co-assembly efficiencies EAKIIH6 (b; n=4), VHAH6 (c; n=2); 
EAKIVH6 (d; n=2) with EAK16-II. A constant amount of histidinylated peptide 
(EAKIIH6, EAKIVH6 or VHAH6) was mixed with increasing ratios of EAK16-II before 
injecting in a larger volume of PBS to trigger fibrillization.  Samples were allowed to 
settle under gravity prior to gel electrophoresis. Peptides were visualized using silver 
staining.  Band intensity was quantified using ImageJ. One way ANOVA and Tukey’s 
multiple comparison test were used to confirm statistical difference (ns: not significant; 
**: p<0.01, ***: p<0.001, compared to molar ratio 32:1).  Figure adapted from reference 
(187) with permission. 
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Figure 5-4 Amino acid sequences and conformations of His-tagged peptides studied.  
(a) Molecular structures of EAK16-II and histidinylated peptides. Peptides are presented 
in β-strand conformation (Molecular Operating Environment; gray: carbon, red: oxygen, 
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blue: amine, light gray: hydrogen).  EAK16-II has a distinctive amphiphilic pattern. The 
hydrophobic face consists of the alanine side chains and the hydrophilic face has the 
glutamic acid and lysine side chains.  At neutral pH, all glutamic acids and lysines are 
ionized. (b) Circular dichrotic spectra of EAKIVH6 and VHAH6.  Each peptide was 
dissolved in PBS at 0.075 mM.  Figure adapted from reference (187) with permission. 
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In vitro His-tag accessibility  
Having established the threshold (32:1) beyond which co-assembly occurred at above 95% 
efficiency, we next studied His-tag accessibility.  Near complete incorporation could be 
assumed in these systems of EAK16-II-diluted EAKIIH6 (40:1, 80:1 and 200:1).  
Accessible His-tags were detected using a fluorescein-conjugated anti-His-tag antibody 
(H6-IgGFITC).  In these and studies described hereafter, the amount of EAK16-II was 
held constant while varying EAKIIH6 in the mixtures.  This was done to maintain non-
specific binding relatively constant.  All groups containing EAKII-16 and EAKIIH6 
exhibited fluorescence.   No significant difference was observed in co-precipitates 
prepared at ratios 40:1 and 80:1, but the fluorescence in 200:1 was reduced significantly 
(Figure 5-5a).  Direct imaging of the precipitates confirmed the differential binding of 
H6-IgGFITC (Figure 5-5b).  His-tag detection was specific; only near background 
fluorescence was observed in fibrils formed with EAK16-II without EAKIIH6 (Figure 5-
5b: “EAK16-II”).  Weak fluorescence was observed in precipitates formed by admixing 
EAK16-II with the non-complementary VHAH6, in which no accessible His-tags were 
appended on the fibrils.  On the other hand, EAKIVH6 incorporated efficiently with 
EAK16-II, rendering strong fluorescence in the co-precipitates.  These data recapitulated 
results of the co-assembly studies (Figure 5-3) and demonstrated that higher amounts of 
EAKIIH6 would not necessarily generate more accessible His-tags.   
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Figure 5-5 Detection of accessible His-tags in co-assemblies in vitro.  (a) Average 
fluorescent intensity samples containing EAK16-II admixed with EAKIIH6 (or 
EAKIVH6 or VHAH6; n=3).  (b) Fluorescent micrographs of co-assemblies incubated 
with αH6-IgGFITC.  Peptides dissolved in PBS were incubated with αH6-IgGFITC with 
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unbound antibodies removed by washing centrifugation.  One-way ANOVA and Tukey’s 
multiple comparison test were used to determine statistical difference (“ns”: not 
significant; **: p<0.01, ***: p<0.001, compared to 80:1 EAK16-II/EAKIIH6).  Figure 
adapted from reference (187) with permission. 
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In vivo His-tag accessibility 
Our previous in vivo studies showed prolonged localization (up to 11 days) of His-tag 
functionalized EAK16-II fibrils when a high relative amount of EAKIIH6 (4:1) was used 
(123).  It was thought that stable co-assembly in the subcutaneous space would require 
abundant EAKIIH6 due to limited mixing of fluid and salts.   To examine this supposition, 
mixtures with diluted EAKIIH6 (40:1, 80:1 and 200:1) were injected subcutaneously into 
the posterior flank of BALB/c mice.  His-tags were adapted with H6-IgG to form a 
platform onto which protein A/G and model therapeutic antibodies could be loaded.  In 
the present study, the stability of the tri-component assemblies (EAK16-II, EAKIIH6, 
and H6-IgG) was monitored using a NIR dye (=800 nm)-labeled anti-rabbit antibody 
(Rabbit-IgG800) that binds to the rabbit-derived H6-IgG.  At all ratios tested, the NIR 
dye-labeled antibody remained at injection site for at least 312 h (Figure 5-6).  The initial 
rapid fluorescence decline (5 min to 24 h; Figure 5-6d) could be attributed to limited 
mixing in the subcutaneous space.  EAK16-II self-assembling requires at least 20 mM of 
NaCl (71).  The lag-time for peptides mixing with critical concentrations of salts would 
result in loss of unbound antibodies (H6-IgG and Rabbit-IgG800) to lymphatic 
drainage.   
    After the initial phase, the formulations performed differently.  From 48 h to 168 h, 
mice injected with the peptides at 40:1 and 80:1 ratios (Figure 5-6a&b: “II” & “III”) 
rendered at least two-fold higher fluorescence compared to those which received only 
EAK16-II (Figure 5-6a&b: “I”).   Fluorescence generated by injecting mixtures at 40:1 
and 80:1 remained above background from 168 h to 312 h.  Injecting the mixture 
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formulated at 200:1 yielded slightly lower fluorescence (Figure 5-6a&b: “IV”), although 
the intensities at all time-points were not significantly different from those in mice 
received 40:1 and 80:1 mixtures (Figure 5-6b).  Differential retention of the His-tagged 
fibrils was evidenced in the respective AUC24h- (Table 5-1).  These results indicated that 
the peptides rendered functional His-tags in living mice, despite diluting the 
histidinylated analogue by 10 to 50 folds. 
    There are three phases in fluorescence decay of antibodies from EAK16-II (Figure 5-6: 
“I”). The intial rapid decrease of fluorescent intensity may be caused by diffusion of 
antibodies at the periphery and those able to diffuse out via large pores.  The plateau 
phase might correspond to antibodies trapped in smaller pores.  The residual decline 
phase could possibly result from fragmentation/dissociation of the membrane, which 
would release antibodies trapped inside.  The similar fluorescence decay profiles in the 
residual phase (192 h – 336 h) of His-tagged membranes (Figure 5-6: “II”, “III”, and 
“IV”) may be attributed to diffusion of antibodies after fragmentation of membranes.  
His-tagged membranes were able to retain higher concentration of antibodies because of 
the non-covalent interactions between His-tags and antibodies.  However, anti-His-tag 
antibodies would dissociate from His-tags and fluorescence labeled secondary antibodies 
would also dissociate from anti-His-tag antibodies eventually.  Antibodies fall off the 
His-tagged membrane would diffuse out the fibrous network similar to non-specifically 
encapsulated antibodies in the EAK16-II membrane (“I”).  Similar diffusion processes 
led to similar fluorescence decay profiles in residual phases. 
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    Injecting H6-IgG and Rabbit-IgG800 alone resulted in fluorescence dissipating to 
near background at 96 h (Figure 5-6a&b: “VIII”).  At the same time point, only marginal 
retention was seen with EAKIIH6 alone (Figure 5-6a&b: “VII”); AUC24h- of the 
fluorescence amounted to less than 20% of that in the most diluted EAK16-II/EAKIIH6 
(200:1; Table 1).  These data were consistent with previous observations that without 
EAK16-II, EAKIIH6 localizes poorly in vivo.  In congruent with results of the His-tag 
accessibility studies in vitro (Figure 5-5), co-administration of EAK16-II and VHAH6 
(80:1) yielded weak fluorescence in vivo (Figure 5-6a&c: “VI; Table 5-1).  In contrast, 
injecting a mixture (80:1) of EAK16-II/EAKIVH6 resulted in sustained fluorescence 
lasting up to 312 h at intensities comparable to mice receiving EAK16-II/EAKIIH6 
(Figure 5-6a&c: “V”).  These data indicated a selective but tolerant mode of EAK16-II -
sheets as acceptors of amphiphilic peptides.   
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Figure 5-6 In vivo real-time detection of His-tags in formulations with diluted 
EAKIIH6.   Solutions containing the peptides, H6-IgG and Rabbit-IgG800 were 
injected into lower flank of BALB/c mice subcutaneously.  Fluorescent intensity was 
quantified using the Pearl Impulse (v2.0) software.  (a) Representative images of mice 
injected with antibodies and EAK16-II (“I”), or EAK16-II/EAKIIH6 (40:1; “II”), or 
EAK16-II/EAKIIH6 (80:1, “III”), or EAK16-II/EAKIIH6 (200:1; “IV”), or EAK16-
II/EAKIVH6 (80:1, “V”), or EAK16-II/VHAH6 (80:1, “VI”), or EAKIIH6 (“VII”).  
“VIII” represents mouse injected with αH6-IgG and αRabbit-IgG800 alone in PBS.  All 
images were exported with the same settings from Licor Pearl Impulse.  Time-lapse 
fluorescence was monitored in mice injected with (b) different ratios of EAK16-II to 
EAKIIH6 and (c) EAKIVH6 or VHAH6 at 80: 1 molar ratio.  “I” and “III” were repeated 
in panel (c) for comparison.  n=4 for all groups except n=5 for group III&VI and n=3 for 
group VIII.  Figure (d) shows the fluorescent decay of all groups in the first 24 h. The 
transient increase in fluorescent intensity in the first 6 h was attributed to an artifact.  
Immediately after injection the local fluorescence exceeded detection threshold.  Over the 
next few hours, the NIR-dye labeled antibody (Rabbit-IgG800) diffused to surrounding 
tissues, resulting in an expanded area of fluorescence of which the intensity was already 
saturating.  Figure adapted from reference (187) with permission. 
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Table 5-1 Peptide formulations used for determining His-tag retention (AUC) in vivo.  
: molar ratio of EAK16-II to EAKIIH6 or control analogue; total volume of peptides and 
antibodies injected = 90 µL. *: Area-under-the-curve (AUC) of fluorescence in mice 
beginning at 24h after subcutaneous injection of EAK16-II/EAKIIH6, H6-IgG, and 
Rabbit-IgG800; FI: fluorescent intensity.  Table adapted from reference (187) with 
permission. 
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Discussion 
We sought to understand the molecular events driving co-assembly of two ionic-
complementarity peptides, one of which contains a C-terminal His-tag.  The goal was to 
maximize co-assembly efficiency such that display of His-tags as protein anchors could 
be optimized.  Ideally all components should be driven into the fibrillar assemblies with 
no fringe aggregates.  Functionalized amphiphilic peptides generally retain the capacity 
to self-sort, either into fibrillar materials (with or without a co-assembling peptide) as 
intended, or into amorphous/bundled aggregates as byproducts.   Dendritic cells and 
macrophages would take up byproducts aggregating into particulates.  The ensuing 
peptide-specific antibody responses would result in material failure, but could also trigger 
autoimmune complications (190).    
    In the current study, we found that self-sorting of EAKIIH6 competed against co-
assembly (Figure 5-7).  Excess EAKIIH6 in low efficient mixtures (4:1 and 8:1) most 
likely diverted from co-assembly into non-fibrillar aggregates.  Self-sorting of EAKIIH6 
could be driven by bundling of the peptide in helical conformation; the large dipole 
moment of EAKIIH6 -helix would diminish (14023 debye, Wen and Meng) when 
dimerized in anti-parallel fashion.  This self-sorting appeared inhibited by EAK16-II in a 
concentration-dependent manner.  With these in mind, we tested peptide mixtures 
containing diluted amounts of EAKIIH6.  It was determined that even when diluted at 40, 
80 and 200-fold, mixing the two peptides resulted in co-assemblies with accessible His-
tags in vitro and in vivo.  Localized His-tags were detectable in living mice for more than 
12 days, comparable to formulations at which a larger amount of EAKIIH6 (4:1) was 
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used. The ability to retain His-tags in vivo for extended duration affords opportunities for 
high dose, local delivery of therapeutic proteins.   
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Figure 5-7 Proposed pathways of EAKIIH6 incorporation into EAK16-II fibrils.   
EAKIIH6 conformational ensemble contains peptide in -helix, -strand, random coil, 
and other secondary structures.  In the absence of EAK16-II or other strong -fibrillizing 
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peptides, EAKIIH6 self-sorts into dimers, oligomers, and high molecular weight species. 
EAK16-II functions as a template; diluting EAKIIH6 in EAK16-II facilitates co-
assembly. In the presence of EAK16-II, helical EAKIIH6 transition into β-strands that are 
stabilized within fibrillizing EAK16-II β-sheets.  Co-assembly efficiency depends on 
extent of excess EAK16-II.  With large excess of EAK16-II, all EAKIIH6 are captured 
into the fibrils.  With low excess of EAK16-II, EAKIIH6 molecules are partially 
incorporated, with some peptides self-sorted into oligomers.  Figure adapted from 
reference (187) with permission. 
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    EAKIIH6 naturally adopts -helix conformation (50).  This is consistent with 
Armstrong and Baldwin’s analysis that C-terminal histidines drive oligopeptides into -
helix conformation (191).  Alpha-helix is stabilized by intra-peptide hydrogen bonds 
between ith amine group and i+4th carbonyl group.  The four amines groups (positive) in 
the N-terminal and four carboxyl groups (negative) in the C-terminal are un-hydrogen 
bonded, which produces a dipole moment (192).  Histidines (pKa ~ 6.5) are charged at 
acidic pH and partially charged at neutral pH, which stabilize α-helix by counteracting 
with the dipole moment.  Raising the pH appeared to relax the stabilizing effect on -
helix as more charged histidines were unionized.  On the other hand, -strand 
conformation was also found in the ensemble of conformations. In the presence of 
EAK16-II, helical EAKIIH6 could conform to the -strand conformation by hydrogen 
bonding with stacked -sheets in the emergent fibrils.  Helix-to-strand conversion has 
been documented extensively in protein-protein oligomerization (193-195).  Formation of 
amyloidal proteins has been shown to be initiated by template-driven conformational 
change.  Gobbi et al have described a “dock-and-lock” model of prion protein (PrP82–146) 
fibrillization in which the locking step entails sequential conformational changes (35, 
196).  The plasticity of EAKIIH6 conformation would facilitate such docking.          
    In the mixing regime of EAK16-II/EAKIIH6 used herein, self-sorting or fibrillization 
of each was suppressed by keeping the ionic strength low in the initial water mixtures.  
Upon transferring to high ionic strength phosphate buffers, the rapid (within 10 seconds 
based on Congo red binding) self-assembling of excess EAK16-II captured EAKIIH6 
molecules.  EAKIIH6 appeared to form oligomers (Figure 5-1b) that could be entrapped 
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in the EAK16-II network en masse, thus removable from supernatant.  A portion of the 
resultant bundled histidines may be inaccessible.  Anti-His-tag antibodies generally 
recognize epitopes containing at least three or four consecutive imidazoles.  The finding 
that 40:1 and 80:1 showed the same His-tag availability in vitro and stability in vivo 
supported the notion that a fraction of the histidines in the 40:1 formulation was buried.  
Thus, the current study identified 80:1 (EAK16-II to EAKIIH6) as the optimum; at this 
ratio stable His-tagged co-assemblies were generated at high co-assembly efficiency.  
Altering the sequence of mixing changed the incorporation efficiency; mixing EAKIIH6 
and EAK16-II that were separately assembled in PBS resulted in poor co-assembly 
efficiency (<52% at 32:1; <18% at 16:1; 0% at 8:1 and 4:1).  In this case, the fast kinetics 
of EAK16-II self-assembling induced by salts in the first step resulting in exclusion of a 
large fraction of EAKIIH6 in the second.   
 
Conclusions 
The current study showed that in vivo co-assembly of the two ionic complementarity 
peptides could be guided by in vitro optimization.  The histidinylated analogue EAKIIH6 
exhibited malleable conformations.  Histidines become deprotonated at basic pH, which 
might induce conversion of α-helix to β-strand.  Self-aggregation of EAKIIH6 could be 
inhibited by the parent peptide in a concentration dependent manner.  Near complete 
incorporation was observed at a molar ratio of 32:1 (EAK16-II: EAKIIH6).  At lower 
ratios, EAKIIH6 may be excluded from the assembly.  Consistent with in vitro 
characterization, diluted formulations were shown to form stable His-tagged membranes 
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in vivo.  The study revealed a formulation by which in vivo display of His-tags was 
attained without excess amphiphilic peptides.  Aggregates from excessive EAKIIH6 
could be problematic.  Studies have shown that protein aggregates augment immune 
response because of crosslinking of B cells by repetitive structures (197, 198).  Anti-
peptide antibodies would compete for binding sites and accelerate the clearance of His-
tagged membrane.  By increasing the efficiency of co-assembly, the likelihood of 
generating immunogenic aggregates outside the main fibrils could be minimized.  
It was proposed that EAKIIH6 adapts β-strand conformation and co-assembles with 
EAK16-II with the “EAK” domain.  This model requires further validation in the future.  
CD and FT-IR only revealed overall conformations instead of the conformation of 
individual peptide.  Incorporation studies using SDS-PAGE also did not provide 
information on orientation and location of EAKIIH6.  High resolution techniques, such as 
solid state NMR with isotope labeling, may be used to fully understand the co-assembly 
(75).   
Besides His-tag, non-ionic linkers might be employed.  Self-assembling peptides were 
functionalized with biotin, which display biotinylated functional motifs via streptavidin 
(96).  Incorporation of functionalized peptides with small non-ionic linker may require 
less parent peptide because of the absence of repulsive forces.  While His-tag provides an 
anchoring mechanism for displaying functional domain (123), direct conjugation of 
functional proteins has also been documented.  When appended with repeating units of 
AEAEAKAK, the fluorogen-activating protein (FAP) L5 (a 25 kDa single-chain variable 
fragment (199)) can be incorporated into EAK16-II fibrils (184).  The design renders 
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FAP displaying fibrillar materials on which the weak fluorescence of the fluorogen 
malachite green is enhanced exponentially.   
Although not specifically determined in the current study, cytotoxicities of EAK16 
analogues have been studied by Zhang and coworkers (34, 183).  Materials from these 
peptides have been used successfully as 3D cellular scaffolds and other applications.  In 
our experiences, EAK16-II/EAKIIH6 fibrils are compatible with epithelial cells and T 
cells (52).  Taken together, the data presented herein demonstrated that co-assembly is a 
versatile strategy for functionalization of fibrils made of ionic complementary peptides.  
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CHAPTER 6  
Summary and Future Directions 
Because of the high specificity and affinity to their target antigens, mAbs represent an 
important and attractive class of immunotherapy in cancer, transplantation management, 
and autoimmune diseases.  However, severe side effects have been reported due to lack 
of specificity at tissue/organ level.  To improve the therapeutic outcomes of mAb, we 
have developed an injectable, biocompatible, and versatile antibody display system using 
the self-assembling peptides, EAK16-II and EAKIIH6.  Antibodies targeting soluble 
antigens or cell surface molecules are all capable of being loaded.  Proof of concept 
characterization studies indicate that antibodies could be stably displayed in subcutaneous 
space and tumor tissue for at least 120 h.  When anti-dAPC antibodies were displayed, 
the trafficking of dAPCs was impeded and the host immune activity was attenuated in a 
mouse skin transplantation model.  The peptide co-assembly had been systematically 
investigated.  His-tagged peptide may adopt β-strand conformations and align with the 
existing amphiphilic parent peptide β-sheets to provide accessible and tunable His-tags.  
Taken together, the performance of antibody display system had been demonstrated and 
the peptide co-assembly had been characterized.  Our findings suggest the antibody 
display system would be a promising platform in improving the therapeutic outcomes of 
mAb. 
To translate the antibody display system into clinical applications, further 
characterization is a prerequisite.  A stepwise optimization will help us define a 
formulation that provides stable antibody display without excessive peptides and proteins.  
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Further characterization of the system may allow us to control density and dose of 
antibodies displayed.  
The in vivo fate of the antibody display system warrants closer examinations.  
Although our data indicate antibodies could be retained at the site of injection for at least 
5 days, the mechanisms of antibody clearance could not be concluded.  The antibody 
display system consists of five components and is stabilized by non-covalent interactions.  
Although the affinity among linker proteins is relatively high, it may still dissociate.  His-
tagged membranes may break down to small fragments.  Another complicating factor is 
the competing binding from intrinsic antibodies.  For example, these antibodies may 
compete for pAG, resulting in accelerated clearance.   Hence, it is necessary to fully 
understand the stability and clearance of the system.  Each component can be tracked 
independently by isotope or dye labeling, which may allow us to identify weaker 
interactions that are responsible for instability. 
We expect the His-tagged membrane would dissociate into fragments and individual 
peptides, which may be cleared by lymphatic drainage and renal clearance.  Nonetheless, 
there is no mechanism to control the degradation process especially considering the 
peptides are relatively resistant to proteolysis (58).   Self-assembling peptides that are 
sensitive to intrinsic enzymes, such as matrix metalloproteinase, have been investigated 
(200).  Alternatively, hydrolytically susceptible peptides, depsipeptide, have been 
synthesized (201).  These strategies may be explored to improve the biodegradability of 
our antibody display system.   
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This antibody display system may serve as a platform for two purposes in clinical 
applications.  First, it may be used as a local antibody delivery system to minimize 
systemic exposure.  Our data show that it could effectively retain antibodies in tumors, 
subcutaneous spaces and the graft-host interface.  The ability to reduce IgG clearance 
opens opportunities for using therapeutic antibodies to modulate disease-associated T 
cells.  These include anti-CTLA-4 IgG that amplifies T cell responses toward cancers.  
Intravenous infusion of these agents has been associated with immune related toxicities 
due to non-specific effects on bystander leukocytes (138).  An effective local depot could 
mitigate these complications.  Second, it may be used as a material strategy to interact 
with target cells.  It had been demonstrated that the trafficking of dAPCs was impeded in 
a mouse skin transplantation model.  Antibodies targeting cell surface molecules could be 
displayed onto the in situ forming membranes to immobilize target cells, such as DCs and 
T cells.  Therefore, immunity that depends on these cells can be modulated.  More 
importantly, this strategy can be used in combination with existing immune modulating 
reagents, for instance, cyclosporine A and tacrolimus.  Each DC may activate 100-3,000 
T cells (170).  By capturing DCs using the antibody display system, doses of immune 
suppressant may decrease to a level that unwanted side effects would be mitigated.  In 
summary, an injectable, biocompatible, and versatile material platform for antibody 
display has been developed and characterized.   It may be utilized to deliver antibodies 
locally to neutralize soluble antigens and display antibodies in situ to interact with target 
cells.  It has the potential to improve therapeutic outcomes of mAbs.  Further 
characterization and optimization would help translate it into clinical applications, such 
as cancer and transplantation.   
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